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Abstract
G protein-coupled receptors (GPCRs) are the largest class of cell-surface receptor proteins
with important functions in signal transduction and often serve as therapeutic drug targets. With
the rapidly growing public data on three dimensional (3D) structures of GPCRs and GPCR-ligand
interactions, computational prediction of GPCR ligand binding becomes a convincing option to
high throughput screening and other experimental approaches during the beginning phases of
ligand discovery. Such predictions are cost-efficient and can be important aides for planning wet
lab experiments to help elucidate signaling pathways and expedite drug discovery. There are
existing computational tools for GPCR ligand binding prediction using various sequence and
structural derived features. However, these methods have been typically tested on specific families
of GPCRs and none has focused on features that characterize binding of a single ligand to multiple
GPCR families. In this work, we have established that there are ligands that bind across two or
more distinct GPCR families. In many cases the involved GPCRs share a conserved sequence
motif and structural similarities. These results suggest possibilities for predicting GPCR ligand
binding through the integration of sequence and 3D structural information. The prediction process
can be guided by features that characterize binding of one ligand to multiple GPCRs of the same
or different families. For my PhD dissertation research, I propose to further explore the
combination of such features to predict GPCR ligand binding. Our computational approach, which
involves integrating GPCR classification, structure predictions, and molecular docking, will be
based on statistical and machine learning as well as energy optimization techniques to predict what
ligands will bind to a given GPCR. The resulting algorithm will be implemented in Python and R
programming packages and incorporated into the publicly accessible GPCR-PEn webserver
(gpcr.utep.edu) for distribution to the scientific community.
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Chapter 1: Introduction
G protein-coupled receptors (GPCRs) are the largest class of cell-surface receptors
(membrane proteins) [Singh et al., 2019] and are encoded by more than 800 genes in the human
genome [Zhang et al., 2015]. More than 50% of the targets of current United States Food and Drug
Administration (FDA) approved drugs are integral membrane proteins [Goodsell et al., 2019]. The
majority of these drug targets fall within four well-studied protein families (GPCRs: 30%; voltagegated ion channels: 8%; ligand-gated ion channels: 7%; and transporters: 7%) [Goodsell et al.,
2019]. GPCR forms the largest portion as they are involved in a wide range of physiological
processes including vision, taste, smell, inflammation, cell recognition, pheromone signaling and
many more.
GPCRs play significant roles in intracellular signaling and are of clinical importance into
many diseases such as cancer [Jo & Jung, 2016] where they have crucial effects on tumor growth
and metastasis [Lappano & Maggiolini, 2012]. Various molecules like hormones, lipids, peptides
and neurotransmitters exert their biological effects by binding to GPCRs coupled to heterotrimeric
G-proteins, which are highly specialized transducers able to modulate diverse signaling pathways
[Lappano & Maggiolini, 2012].
Insel et al. (2018) used TaqMan qPCR arrays to quantify the mRNA expression of ∼340
GPCRs and found that human chronic lymphocytic leukemia (CLL) cells, breast cancer cell lines,
colon cancer cell lines, pancreatic ductal adenocarcinoma (PDAC) cells, cancer associated
fibroblasts (CAFs), and PDAC tumors express 50 to over 100 GPCRs, including many orphan
GPCRs that lack known physiologic agonists. These authors proposed that highly expressed
GPCRs in cancer cells (for example, GPRC5A in PDAC and colon cancer cells and GPR68 in
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PDAC CAFs) may contribute to the malignant phenotype and may serve as biomarkers or possible
novel therapeutic targets for the cancer treatment.
Besides cancer, GPCRs are involved in other diseases and their treatments. For instance,
GPCRs are targeted for treating osteoporosis where they serve as anabolic drug targets in
osteoporosis [Diepenhorst et al., 2018]. GPCRs have been implicated in the pathogenesis of
Alzheimer’s disease (AD) and in multiple stages of the hydrolytic processing of the amyloid
protein precursor (APP), a precursor protein involved in the formation of amyloid plaques found
in AD patients’ brain [Zhao et al., 2016]. Accumulated data have shown that GPCRs can bind to
β-secretase (β-site APP cleaving enzyme 1, BACE1) and γ-secretase which are key enzymes in
the hydrolytic processing of APP [Zhao et al., 2016]. Similarly, GPCRs are implicated in the
pathophysiology of various neurodegenerative diseases which involves frontotemporal dementia,
vascular dementia, Parkinson’s disease, and Huntington’s disease [Huang et al., 2017].
Freudenberg et al. (2018) suggests that galanin, an endogenous ligand for the GPCR
galanin receptor type 2 (GALR2), plays an important role in epilepsy, confirming an earlier
suggestion that galanin is a potential target to treat epilepsy [Mazarati et al., 2001]. In particular,
galanin depletion from the hippocampus may contribute to the maintenance of seizure activity
[Clynen et al., 2014], and there is genetic evidence showing that a galanin loss-of-function
mutation leads to epilepsy in humans [Guipponi et al., 2014]. This is one of the examples indicating
that understanding GPCRs ligand binding could have significant impacts on the modern medical
field.
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1.1 GPCR STRUCTURAL CHARACTERISTICS
All GPCRs share the same characteristic molecular structure consisting a N-terminus,
cytoplasmic C-terminus along with seven hydrophobic transmembrane (7TM) domains which are
linked through three intracellular and three extracellular loops (Figure 1.1).

Figure 1: G protein-coupled receptor without ligand [C. Vines, Personal Communication,
November 7, 2020]
Interesting insights into the impact of the three-dimensional (3D) structures of protein
targets important for discovery of new drugs (e.g., GPCRs) has been revealed due to open access
to structural data [Goodsell et al., 2019]. These includes GPCR ligand binding modes, G-protein
binding mechanisms, structural similarity and diversity of the GPCR ligand recognition, GPCR
functional states, and characteristics of a receptor structure that is competent for G-protein binding
[Zhang et al., 2015].
1.2 CLASSIFICATION OF GPCRS
Several classification systems have been used to sort out the superfamily of GPCR proteins.
One of the most frequently used systems is the International Union of Basic and Clinical
Pharmacology (IUPHAR) [Horn et al., 2003], which divided GPCRs into six major classes, A
(rhodopsin-like), B (secretin receptor family), C (metabotropic glutamate), D (fungal mating
pheromone receptors), E (cyclic AMP receptors), and F (frizzled/smoothened) based on sequence
homology and functional similarity.
3

Another system of classification is the GRAFS system. The GRAFS system clusters
GPCRs in five main families that we term Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2, and
Secretin [Fredriksson and Lagerstrom 2003]. The main difference between the IUPHAR system
and the GRAFS system is that, IUPHAR is designed to cover all GPCRs, in both vertebrates and
invertebrates, whereas GRAFS is designed towards mammalian species. Table 1 gives a
breakdown of the number of GPCRs in each class of GPCRs stored in the GPCR-PEnDB (Begum
et al, 2020).
GPCR-PEn (GPCR Prediction Ensemble) is a webserver developed by our team which
utilizes sequence similarity, transmembrane structure, and dipeptide composition to determine if a
protein sequence is a GPCR (www.gpcr.utep.edu). It has a database component called GPCRPEnDB (GPCR Prediction Ensemble Database), a searchable MySQL database of confirmed
GPCRs and non-GPCRs [Begum et al., 2020]. It was constructed by our team with the goal of
allowing users to conveniently access useful information of GPCRs in a wide range of organisms
and to compile reliable training and testing datasets for different combinations of computational
tools [Begum et al., 2020]. My work is to extend the information on GPCRs to cover their 3D
structures, interactions with ligands and develop a combined statistical and machine learning
approach, based on both sequence and structure information for predicting ligands for GPCRs.
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Table 1: Number of GPCR subfamilies, sub-subfamilies, subtypes, and sequences in the extended
IUPHAR and GRAFS classification families [Begum et al., 2020].

Subfamilies

Subsubfamilies

Subtypes

No. of
Sequences

IUPHAR

GRAFS

Class A

Rhodopsin-like

11

61

287

2493

Adhesion-like

1

5

15

91

Secretin-like

1

9

33

113

Class C

Glutamate-like

4

5

22

112

Class D

Fungal
pheromone*

1

1

1

13

Class E

cAMP receptor*

1

1

1

11

Class F

Frizzled

1

1

11

82

Class T2R**

Taste2 receptor**

1

1

25

211

Class B

*Not in the original GRAFS system
**Not in original IUPHAR or GRAFS system

1.3 LIGANDS BINDING TO GPCRS
GPCRs are known to bind to G proteins inside the cell, and outside the cell to ligands that
include a variety of molecules such as ions, biogenic amines, peptide, hormones, growth factors,
lipids, and photons, a quantum of light [Huang et al., 2017]. Figure 2 is an example of a GPCR
(Crystal Structure of mGluR5) 3D structure showing ligands (green) bound to it. However, there
are some GPCRs with no known information to date on ligands binding to them [Gad & Balenga,
2020].
In this study we obtained data on GPCR ligand interactions from three public different
databases: BindingDB, GLASS, and GPCRdb. BindingDB contains a collection of experimental
protein-small molecule interactions and measured binding affinities, focusing chiefly on the
interactions of proteins considered to be candidate drug-targets with ligands that are small, druglike molecules [Gilson et al., 2016]. GPCRdb provides reference data in an integrated, annotated
5

and structured fashion, with a focus on sequences, structures, single-point mutations and ligand
interactions [Munk et al., 2016]. GLASS (GPCR-Ligand ASSociation) is considered to be the most
comprehensive and up to date GPCR-ligand association repository in the field, encompasses a
broad range of GPCR-related pharmacological data, gathered from a multitude of data sources and
PubMed literature mining [Chan et al., 2015].

Figure 2: Crystal Structure of mGluR5 with ligands bound (green) to it, PDB ID: 6FFI
[Sehnal et al., 2018; Christopher et al., 2018]
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1.4 RESEARCH OBJECTIVES
The ultimate goal of my PhD research is to develop a computational method to predict
what ligands will bind to a given GPCR with experimentally determined or computationally
predicted structure. A number of machine learning type algorithms of predicting GPCR-ligand
binding such as random forest, convolutional neural network, deep neural network, decision tree,
and support vector machine [Seo et al., 2018; Li et al., 2019; Raschka & Kaufman, 2020] have
been developed recently, but they have been tested only on specific groups of GPCRs. The aim of
my research is to establish an integrated approach that combine sequence and 3D structural features
to make reliable predictions for GPCR-ligand binding in general.
To make such predictions possible, we first have to collect available data about GPCRligand binding and identify GPCR sequence and structural features that can shed light on the
binding affinities, binding sites, and binding poses of the ligands. The information collected above
will be used to drive the development of a combined statistical and machine learning approach,
based on both sequence and structure information for predicting ligands for GPCRs. After
implementation and testing, this prediction program will be added to the GPCR-PEn to be
distributed publicly to the scientific community.
In Chapter 2 of this document, I will present a review on current GPCR-ligand binding
prediction methods. This is followed by a description of my work in preparing the data and
exploring the computational tools in Chapters 3 and 4, and a plan for my dissertation research in
Chapter 5.
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Chapter 2: Literature Review
This chapter reviews the different approaches and algorithms for predicting protein-ligand
binding site, and databases we gathered data from. The first section focuses on the biological
importance of protein-ligand binding. The second section covers the different protein-ligand
binding site prediction methods, which is followed by the third section which has the information
about the sources of data. Lastly, the fourth section focuses webservers which predicts proteinligand binding site.
2.1 PROTEIN LIGAND BINDING
Proteins play an essential role in all cellular activity, which includes: enzymatic catalysis,
maintaining cellular defenses, metabolism and catabolism, signaling within and between cells, and
the maintenance of the cells’ structural integrity [Roche & McGuffin, 2016; Roche et al., 2011;
Roche et al., 2012; Roche et al., 2013]. Protein ligand binding is essential to many life processes
in living organisms [Nguyen et al., 2017]. They are required for many proteins to function properly
[Kukol, 2014]. Protein ligand interactions are a necessary prerequisite for signal transduction,
immunoreaction, and gene regulation [Fu et al., 2018]. Protein ligand interaction studies are
important for understanding the mechanisms of biological regulation, and they provide a
theoretical basis for the design and discovery of new drug targets [Fu et al., 2018].
GPCRs play an important role which involves binding to ligands and activating signal
transduction pathways and cellular responses [Seo et al., 2018]. For example, galanin, an
endogenous ligand for the GPCR galanin receptor type 2 (GALR2), plays an important role in
epilepsy [Freudenberg et al., 2018; Mazarati et al., 2001]. In humans, the initial phase in human
visual perception includes photon retention by four distinctive visual pigment [Srinivasan et al.,
2019]. These visual pigments include an apoprotein, opsin, covalently bound to the chromophore
11-cis-retinal (11CR), a vitamin A derivative that functions as an inverse agonist locking the
photoreceptor opsin protein in its inactive state [Srinivasan et al., 2019]. Similarly, inhaled
8

selective b2-agonists (e.g., salbutamol, formoterol, indacaterol etc.) are usually used in the
treatment of obstructive airway diseases like asthma [Matera et al., 2018]. These drugs bind to the
b2-adrenoceptor (b2-AR) and causes the activation of certain G-proteins and subsequent
generation of cyclic adenosine monophosphate (cAMP) in airway smooth muscle leading to
bronchodilation [Matera et al., 2018]. Figure 3 shows a ligand (green) bound to a protein.

Figure 3: Docking of a small molecule (green) into the crystal structure of the beta-2 adrenergic
G-protein coupled receptor (PDB: 3SN6, source: Wikipedia)
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2.2 PROTEIN LIGAND BINDING SITE PREDICTION
Protein ligand interaction is fundamental for many proteins to carry out their biological
function [Kukol, 2014]. This interaction is generally specific, in terms of the ligand involved, and
the location the interaction takes place [Kukol, 2014]. The detection of ligand-binding sites is often
the starting point for protein function identification and drug discovery [Brylinski & Skolnick,
2008]. In order to gain knowledge about the interactions and, by extension, the protein’s function
and how it influences the activity of the protein, efforts have been made to develop methods that
can predict ligand binding sites of proteins computationally [Kukol, 2014]. As a result of the
location specificity of the ligand binding sites, these methods make use of one or more of the
following properties in order to distinguish the binding site from other parts of the protein surface;
evolutionary, geometric, energetic, and statistical [Kukol, 2014]. These methods have been
classified into one of the following categories: template-based, geometry-based, energy-based,
propensity-based, and combination-based and others [Kukol, 2014].
2.2.1 Template-based method
Template-based methods utilize homologous and/or similar structures with known binding
sites [Kukol, 2014]. Protein sequence are homologous if they descended, usually with divergence
from a common ancestral sequence [Lee et al., 2007]. Homologues can be further divided into
orthologues and paralogues [Lee et al., 2007]. Orthologues are found in different species and have
been separated by a speciation event, rather than by gene duplication [Lee et al., 2007]. Paralogues
are the product of gene duplication within a species, but because gene duplication can occur before
speciation, paralogues can also exist in different species [Lee et al., 2007].
The basic idea behind all template-based methods for predicting ligand binding site is that
proteins that share sequence homology are known to adopt similar 3D structures and usually
perform similar biological functions [Lee et al., 2007]. Firstly, we identify a ligand-bound complex
structures (to serve as a template to find potential ligand binding sites) that share sufficient
10

sequence similarity with the target protein (the protein in which ligand binding sites are to be
predicted). Secondly, we superimpose the target protein and identified templates including
information on known ligand binding sites, and lastly, a consensus ligand binding site can be
revealed and its characteristics as a putative ligand binding site for the target protein is evaluated
by comparison to those of known ligand binding sites [Kukol, 2014]. There are a number of
templated-based methods. These includes 3DLigandSite [Wass et al., 2010;Wass & Sternberg,
2009], FINDSITE [Brylinski & Skolnick, 2008; Skolnick & Brylinski, 2009], Firestar [López et
al., 2007], I-TASSER [Zhang, 2007], ProBiS [Konc & Janežič, 2010], and IntFOLD [Daniel B.
Roche et al., 2011].
These methods are similar in principle (i.e., they all use templates) but differ in
implementation. For example, 3DLigandSite combined the use of the predicted structure of the
targets with both residue conservation and the location of ligands bound to homologous structures
[Wass et al., 2010;Wass & Sternberg, 2009] whereas FINDSITE is a method for ligand-binding
site prediction and functional annotation based on binding-site similarity across groups of weakly
homologous template structures identified from threading [Brylinski & Skolnick, 2008; Skolnick
& Brylinski, 2009].
2.2.2 Geometry-based method
Geometric-based methods focus on identifying pocket(s) on the protein surface that can
accommodate small ligand molecules by computing some types of geometric measures.
Statistically, studies on Protein Data Base protein-ligand complex structures have shown that small
molecule ligands tend to bind at deflated regions of protein surface, particularly, its largest and/or
deepest cavities [Kukol, 2014]. Generally, the first step in this category is to identify an empty
space on the protein surface. The next step is to cluster the empty spaces to identify the largest
pocket or cavity, which is often assigned as the best (top-ranked) predicted ligand binding site
[Kukol, 2014]. LIGSITECSC [Hendlich et al., 1997], PocketPicker [Weisel et al., 2007], VICE
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[Tripathi & Kellogg, 2010], SCREEN [Nayal & Honig, 2006], POCASA [Yu et al., 2010], CASTp
[Binkowski et al., 2003], MSPocket [Zhu & Pisabarro, 2011], and fpocket [Le et al., 2009 are all
examples of geometry-based method.
2.2.3 Energy-based method
The focus of energy-based methods is to find patches on the protein surface that are
favorable for ligand binding [Kukol, 2014]. This is done by devising a probe molecule and
computing the interaction energy between the surrounding protein atoms and the probe [Kukol,
2014]. These methods include SiteHound [Ghersi & Sanchez, 2009], Q-SiteFinder [Laurie &
Jackson, 2005], Morita’s method [Morita et al., 2008], and FTSite [Ngan et al., 2012].
2.2.4 Propensity-based method
Propensity-based method deals with the statistics of certain properties for their propensities
to be at, or associated with, known ligand binding sites [Kukol, 2014]. These methods often rerank the pockets, predicted by other methods, by finding statistically significant differences
between ligand binding site and non-ligand binding site [Kukol, 2014]. Propensity-based methods
include STP [Mehio et al., 2010], LISE [Xie & Hwang, 2012; Xie et al., 2013], and Hirayama’s
method [Soga et al., 2007].
2.2.5 Combination-based and others
These methods combine two or more methods to predict ligand binding site. The idea is
that, for example, geometry and energy are two distinct attributes of ligand binding sites and
because different methods may complement and/or compensate each other, it is not surprising that
a combination of these methods can prove successful in ligand binding site prediction [Kukol,
2014]. Examples include ConCavity [Capra et al., 2009], MEDock [Chang et al., 2005],
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Thornton’s method [Gutteridge et al., 2003], and MetaPocket 2.0 [Huang, 2009]. MetaPocket 2.0
reports the consensus of the results of 8 different methods [Huang, 2009; Kukol, 2014].
2.3 GPCR LIGAND BINDING PREDICTION
A significant advance for studying GPCRs as a drug target is the identification of ligands
that bind to GPCR [Seo et al., 2018]. Many biochemistry or bioinformatics approaches to
identification of drug-receptor binding have been proposed, which focus on calculating proteinligand binding affinity, that largely rely on 3D structures of proteins or ligands [Seo et al., 2018].
Present day computational databases contain huge number of molecules and are freely accessible,
which makes computer-aided ligand discovery a compelling alternative to high throughput
screening and other experimental approaches during the early stages of ligand discovery [Raschka
& Kaufman, 2020].
There are two major approaches for computer-aided ligand discovery. These are ligandbased virtual screening and structure-based virtual screening [Raschka & Kaufman, 2020]. Ligandbased virtual screening approaches focus on the structure and physicochemical properties of
ligands in the absence of the receptor structure whereas structure-based virtual screening assumes
knowledge of the receptor structure, for example, molecular docking [Raschka & Kaufman, 2020].
Structure-based virtual screening uses scoring functions to identify favorable ligand candidates for
the protein. These scoring functions are grouped into four classes: force field, empirical,
knowledge-based, and machine learning-based [Raschka & Kaufman, 2020].
In recent years, machine learning has been used to augment both ligand-based virtual
screening and structure-based virtual screening [Li et al., 2019; Raschka & Kaufman, 2020]. The
techniques used include random forest, convolutional neural network, deep neural network,
decision tree, and support vector machine [Seo et al., 2018; Li et al., 2019; Raschka & Kaufman,
2020]. Some of these scoring functions are based on a set of descriptors derived from the proteins
and ligands. The descriptors represent the properties of atoms in the protein-ligand complexes
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[Hassan, 2018; Jiménez et al., 2017], structures of ligands and amino acid motif sequences of
GPCRs (Figure 4 & 5) [Seo et al., 2018]. Some of these descriptors include the following [Seo et
al., 2018; Hassan, 2018; Jiménez et al., 2017]:
•

Hydrophobic (aliphatic or aromatic C)

•

Aromatic (aromatic C)

•

Hydrogen bond acceptor (acceptor 1 H-bond or S spherical N; acceptor 2 H-bonds
or S spherical O; acceptor 2 H-bonds S)

•

Hydrogen bond donor (donor 1 H-bond or donor S spherical H with either O or N
partner)

•

Positive ionizable (Gasteiger positive charge)

•

Gasteiger negative charge (Gasteiger negative charge)

•

Metallic (Mg, Zn, Mn, Ca, or Fe)

•

Excluded volume (All atom type)

•

Hub and cycle structures of ligands and amino acid motif sequences of GPCRs

Figure 4: Examples of hub and cycles and how they are encoded [Seo et al., 2018].
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Figure 5: Graphical feature representations (a) Hydrophobic, (b) Aromatic, (c) Positive
Ionizable, (d) Hydrogen Bond Acceptor, (e) Hydrogen Bond Donor, (f) Negative Ionizable, (g)
Metal, (h) Occupancy [Hassan, 2018].
2.4 PROTEIN LIGAND DOCKING
The objective of protein ligand docking is to predict the position and conformation of a
ligand when it is bound to a protein receptor or enzyme [Taylor et al., 2002; Forli et al., 2016].
Several protein ligand docking applications are available such as AutoDock and AutoDock Vina
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[Morris et al., 2009; Trott & Olson, 2009], rDock [Ruiz-Carmona et al., 2014], Surflex [Spitzer &
Jain, 2012] and Glide [Friesner et al., 2004, 2006]. These applications calculate the site, geometry
and energy of ligands or peptides interacting with proteins. They have been used in docking
GPCRs with its associated ligands. There are some that are specific for GPCRs such as IPHoLD,
an Integrated Protein Homology modeling, Ligand Docking and protein design approach which
models induced fit and conformational selection ligand binding modes from homolog receptor
structures only [Feng et al., 2017]. Figure 6 shows an illustration of protein ligand docking.

Figure 6: Schematic illustration of docking a small molecule ligand (green) to a protein target
(black) producing a stable complex (source: Wikipedia)
2.5 PROTEIN STRUCTURAL COMPARISON
Comparative analyses of protein sequences and structures assumes a central role in
understanding proteins and their functions [Hasegawa & Holm, 2009]. Assuming an evolutionary
continuity of structure and function, describing the structural similarity relationships between
protein structures allows scientists to infer the functions of newly discovered proteins [Holm &
Laakso, 2016]. Several protein structural comparison programs have been developed such as CE
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[Shindyalov & Bourne, 1998], DALI [Holm & Sander, 1993], MultiProt [Shatsky et al., 2002],
and FATCAT [Ye & Godzik, 2003; Ye & Godzik, 2004]. Some of these programs, FATCAT for
example, accommodate flexibility and structural rearrangements of the proteins. FATCAT
optimize the alignment and minimize the number of rigid-body movements (twists) around pivot
points (hinges) introduced in the reference protein [Ye & Godzik, 2003; Ye & Godzik, 2004].
Figure 7 show a flexible and a rigid structural alignment of GPCRs with PDB IDs 6W2X and
7C7S.

Figure 7: FATCAT Structural alignment of PDB: 6W2X and PDB: 7C7S (Left: Rigid, Right:
Flexible)
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2.6 MOTIF SEARCH
GPCRs retain a wide variety of functional domains within and across species to bind with
diverse ligands, activate G-proteins, and participate in signaling pathways [Nagarathnam et al.,
2011]. Most members of the rhodopsin-like (Class A) family of GPCR have inside their
transmembrane domain (TMD) a number of highly conserved motifs, such as a DRY motif at the
TMD3 [Römpler et al., 2006]. It has been found that mutations to the DRY motif increases the
basal activity of the mammalian orthologs of the chemoattractant receptor GPR33 in mouse and
Gerbillinae species before the receptor became pseudogenized in the Gerbillinae subfamily
[Römpler et al., 2006]. The motif search algorithm is looking for a set of similar subsequences in
a set of much longer sequences [Bailey et al., 2006]. One of the most widely used tools for
searching for novel motif in sets of biological sequences is MEME (Multiple EM for Motif
Elicitation) [Bailey et al., 2006; Bailey et al., 2009; Bailey et al., 2015].
2.7 DATABASE
In this subsection we talk about the source of the dataset we have gathered during the study.
2.7.1 UniProtKB/Swiss-Prot
The Universal Protein Resource (UniProt) is a comprehensive resource for protein
sequence and annotation data [Bateman, 2019]. The UniProt Knowledgebase (UniProtKB) is the
database of UniProt. This is the central hub for the collection of functional information on proteins,
with accurate, consistent and rich annotation [Bateman, 2019]. Over 95% of the entries on
UniProtKB are derived from the translation of the coding sequences (CDS) which have been
submitted to the public nucleic acid databases, the EMBL-Bank/GenBank/DDBJ databases
[Bateman, 2019]. Each entry contains mainly, the amino acid sequence, protein name or
description, taxonomic data and citation information [Bateman, 2019]. As of December 7, 2020,
this database has reviewed 563,972 sequences with another 209,157,139 unreviewed sequences
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which are available through TrEMBL. We obtained data on the start and end of regional sequence
(the N-terminal, extracellular loops, intracellular loops, the seven helices, and the C-terminal) of
the GPCRs.
2.7.2 RCSB PDB
Protein Data Bank (PDB) is a single worldwide repository of information about the 3D
structures of large biological molecules, including proteins and nucleic acids, which is found in all
organisms including bacteria, yeast, plants, flies, other animals, and humans [Berman et al., 2000].
The structures in the PDB archive range from tiny proteins and bits of DNA to complex molecular
machines like the ribosome [Berman et al., 2000]. The archive is freely available to users and is
updated weekly. Under the leadership of Helen M. Berman, the Research Collaboratory for
Structural Bioinformatics (RCSB) became responsible for the management of the PDB in 1998.
As of December 7, 2020, PDB contains 171,916 structures.
2.7.3 BindingDB
BindingDB is a publicly accessible database of experimental protein-small molecule
interaction database of measured binding affinities, focusing chiefly on the interactions of proteins
considered to be candidate drug-targets with ligands that are small, drug-like molecules [Gilson et
al., 2016]. BindingDB data entries are primarily derived from scientific articles and, increasingly,
US patents [Gilson et al., 2016]. These data come from a variety of measurement techniques,
including enzyme inhibition and kinetics, isothermal titration calorimetry, NMR, and radioligand
and competition assays [Gilson et al., 2016]. As of December 7, 2020, BindingDB contains data
on 2,096,653 binding interactions for 8,185 proteins and over 920,703 drug-like molecules.
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2.7.4 GPCRdb
GPCRdb provide reference data in an integrated, annotated and structured fashion, with a
focus on sequences, structures, single-point mutations and ligand interactions [Munk et al., 2016].
It has web tools for swift analysis of structures, sequence similarities, receptor relationships, and
ligand target profiles, and facilitate dissemination through inter active diagrams of, for example,
receptor residue topologies, phylogenetic relationships and crystal structure statistics [Munk et al.,
2016]. GPCRdb holds a large collection of manually annotated mutations from published studies
that have served to pin-point ligand binding sites, specific ligand-receptor interactions or the
residues responsible for subtype selectivity [Isberg et al., 2016; Munk et al., 2016]. This database
releases and updates data bi-monthly and they have 28,015 proteins, among which 423 are human
proteins with a total of 4,622 species, and 25,087 ligand interactions, as of December 7, 2020.
2.7.5 IUPHAR/BPS
The International Union of Basic and Clinical Pharmacology (IUPHAR) and the British
Pharmacological Society (BPS) have jointly developed the Guide to PHARMACOLOGY which
is an open-access, expert-curated database of molecular interactions between ligands and their
targets [Armstrong et al., 2020]. It is intended as a “one-stop shop” portal to pharmacological
information and its main aim is to provide a searchable database with quantitative information on
drug targets and the prescription medicines and experimental drugs that act on them [Armstrong
et al., 2020]. G protein-coupled receptors are one of the six major pharmacological targets into
which the Guide is divided, with the others being: ion channels, nuclear hormone receptors,
catalytic receptors, enzymes and transporters [Alexander et al., 2019]. This database contains
2,976 targets of which 394 are GPCRs, 10,659 ligands, 8,959 ligands with target interactions, and
many more, as of December 7, 2020.
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2.7.6 GLASS
GLASS (GPCR-Ligand ASSociation) encompasses a wide breadth of GPCR-related
pharmacological data, gathered from a multitude of data sources and PubMed literature mining
[Chan et al., 2015]. GLASS the most comprehensive and up to date GPCR-ligand association
repository in the field [Chan et al., 2015]. This database contains 562,871 unique GPCR-ligand
entries, 1,046,026 experimental data entries, 3,056 GPCR entries (of which 825 are human GPCR),
and 342,539 ligand entries, as of December 7, 2020.

2.7.7 GPCR-PEnDB
GPCR-PEnDB (GPCR Prediction Ensemble Database) is a searchable MySQL database of
confirmed GPCRs and non-GPCRs [Begum et al., 2020]. GPCR-PEnDB currently contains 3129
confirmed GPCR and 3575 non-GPCR sequences collected from the UniProtKB/Swiss-Prot
protein database, encompassing over 1200 species [Begum et al., 2020]. The non-GPCR entries
include transmembrane proteins for evaluating various prediction programs’ abilities to distinguish
GPCRs from other transmembrane proteins [Begum et al., 2020]. Each protein is linked to
information about its source organism, classification, sequence lengths and composition, and other
derived sequence features [Begum et al., 2020].
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Chapter 3: Materials and Methods
In this chapter we describe the construction of our dataset: GPCR ligand interaction and
3D structures. This is followed by a description of methods of motif search, 3D structural
comparisons, and protein ligand docking.
3.1 DATASET COLLECTION
In order to undertake the study, I collected publicly available datasets on 3D structures of
GPCR with their known ligands that bind to them. In this subsection we throw more light on what
types of data we needed and explain the purposes they serve. Data on GPCR ligand interactions
were gathered and restructured to facilitate computational analyses, and to determine ligands that
bind to GPCRs across three different IUPHAR families. Also, data on the ligand’s SMILES
(Simplified Molecular Input Line Entry Specification) were gathered to generate their 3D
structures for molecular docking. We also gathered data on the actions of the ligands on the
GPCRs, that is, whether they are agonist, full agonist, partial agonist, antagonist, inverse agonist,
biased agonist, neutral, positive, and negative, to classify the ligands. Data on binding residues of
GPCR ligand interactions were gathered. This was to help compare GPCRs that bind to the same
ligands. Available 3D structures of GPCRs were gathered for structural comparison, and for
molecular docking. Lastly, we obtained the sequences of the confirmed GPCRs and the start and
end of the regional sequence (the N-terminal, extracellular loops, intracellular loops, the seven
helices, and the C-terminal) of the confirmed GPCRs for motif search.
3.1.1 Data Sources
Six datasets have been collected and saved. Below is a description of the datasets:
1. The first dataset contains available 3D structural data on GPCR from Research Collaboratory
for Structural Bioinformatics Protein Data Bank (PDB). This includes the PBD IDs of the
GPCRs and data on their experimental structural factors.
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2. The second one was collected from BindingDB which contains data on the ligands that bind to
the GPCR. These data include the binding affinities, the ligand molecular weight, and SMILES
(Simplified Molecular Input Line Entry System).
3. The third one was from GLASS (GPCR-Ligand ASSociation) which also contains data on the
ligands that bind to GPCR. These data include ligand IDs, and binding affinities.
4. The fourth one was collected from IUPHAR/BPS which contains data on the actions of the
ligands on the GPCRs, that is, whether they are agonist, full agonist, partial agonist, antagonist,
inverse agonist, biased agonist, neutral, positive, and negative.
5. The fifth one was collected from GPCRdb which contains the binding residues of the GPCR
ligand binding.
6. Lastly, we obtained the sequences of the confirmed GPCRs from GPCR-PEnDB (GPCR
Prediction Ensemble Database; gpcr.utep.edu/database) which were obtained from
UniProtKB. Also, we obtained from UniProtKB data on the start and end of the regional
sequence (the N-terminal, extracellular loops, intracellular loops, the seven helices, and the Cterminal) of the GPCRs.
Data on the sequences of the GPCRs were saved as a single fasta file whereas the binding
residues of GPCR ligand interactions were saved as a single csv (comma separated values) file.
For the 3D structural data, we first saved their PDB ID as a single csv file, and then saved their
experimental data on their structural factors as a pdb file. Data on the start and end of the regional
sequence were saved as a text file. All other data were saved together as a single csv file.
3.1.2 Procedures for data acquisition
We obtain a list of UniProt IDs of confirmed GPCRs from our database (originally, from
UniProtKB); GPCR-PEnDB, with this list we searched PDB for each one of them if there exist a
3D structure for it, using the advance search available on PDB. From the search result, we selected
PDB ID, experimental method, ligand ID, and Accession code(s) through the custom table option
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and downloaded the resulting csv file. After performing some exploratory data analysis (on each
column/variable) on the data, we realized that the column in the data for UniProt ID contains
multiple UniProt IDs. For this reason, we took that column and crosscheck with the list of
confirmed GPCRs to eliminate any non-GPCR in the list. After doing this we then crosscheck the
result from the elimination to confirm if there is an entry on PDB for each of the UniProt IDs we
found. After confirming the result, we then use the advance search to search and download data
on each at a time to avoid the situation described above. We then downloaded data on their 3D
structure. The protein sequence of the confirmed GPCRs were obtained from GPCR-PEnDB
(which are originally from UniProtKB). Also, data on the start and end of regional sequence (the
N-terminal, extracellular loops, intracellular loops, the seven helices, and the C-terminal) of the
GPCRs were obtained from UniProtKB.
To obtain data from BindingDB, we had to create an account with them to get access to the
data. We search for each of the confirmed GPCR on their site using the UniProt IDs of the GPCRs.
After getting a hit, we must enter our login credentials and security code generated by the site,
each time we want to download data on the hit. The data comes in a tsv (tab separated values) file.
On GPCRdb we navigated to GPCR ligand interaction and selected each of the
precalculated interactions that has been annotated on their website at a time. Upon selection, it
shows the interaction of the target (receptor) with a ligand. Under the ligand interaction browser
on their website, we downloaded a csv file of the ligand interaction with the target, which contains
the residues.
In the case of IUPHAR/BPS, we navigated their website to “download data and reports”
through “downloads” which is under “resources”. On the “download data and reports” page we
downloaded data on “complete ligand list”, and “all interaction data for ligands and targets”, which
were listed under the subheading “Download data files”. The interaction data contains information
on whether the ligand is an antagonist or agonist.
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3.1.3 Exploratory data analysis and data restructuring
After obtaining all the necessary data (mentioned above) required for this study, we
performed exploratory data analysis on it. PDB IDs of GPCRs obtained from PDB were cleaned
to eliminate duplicates from them. Ligand data obtained from BindingDB, IUPHAR/BPS, and
GLASS were restructured to have each of the different types of binding affinities (e.g., EC50,
IC50, Ki, Kd, pKb, pEC50, pKi, pIC50, pKd, potency, activity (in %), and inhibition (in %).) in
one column. The binding affinities were cleaned of relational symbols (e.g., >, <, etc.) and put in
a new column. After restructuring we merged together ligand data from BindingDB,
IUPHAR/BPS, and GLASS based on the GPCR IDs. The resulting data was cleaned of duplicates
and saved as csv file. We used R programming language to perform the exploratory data analysis
and data restructuring.
3.2 POPULATING GPCR-PENDB
GPCR-PEnDB (GPCR Prediction Ensemble Database; gpcr.utep.edu/database) is a
searchable MySQL database that contains the amino acid sequences and derived features of 3129
confirmed GPCRs and 3575 non-GPCR proteins to serve as training and testing data for
developing new computational ensemble approaches for GPCR prediction and classification. This
previous version of GPCR-PEnDB, however, did not provide access to any three-dimensional (3D)
structure information. In the current project, we have incorporating all the available GPCR
structures deposited in the PDB into GPCR-PEnDB with the aim of facilitating the prediction of
GPCR-ligand binding.
For this purpose, we have searched and collected all the available GPCR structures and the
associated PDB IDs for our confirmed GPCR sequences using their UniProt IDs. We incorporated
a field containing the PDB IDs of the structures into GPCR-PEnDB and hyperlinked them to their
PDB entries.
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3.3 MOTIF SEARCH
In the course of the exploratory data analysis, we observed that there were some ligands
that bind to GPCRs of two or more distinct IUPHAR families. As a result, we decided to perform
a motif search across the GPCRs these ligands bind to, to ascertain whether there are significant
motifs that go across different IUPHAR families. We focused on ligands that bind to GPCRs of
three distinct IUPHAR families. In doing this we used Multiple Expression motifs for Motif
Elicitation (MEME) system to search for motifs. MEME works by searching for repeated,
ungapped sequence patterns that occur in the DNA or protein sequences provided by the user
[Bailey et al., 2006; Bailey et al., 2009; Bailey et al., 2015]. We took three approach in our motif
search:
1. Perform a motif search on the entire sequence of the GPCRs.
2. Perform a motif search on regional sequence (the N-terminal, extracellular loops,
intracellular loops, the seven helices, and the C-terminal) of the GPCRs.
3. Perform a motif search on modified regional sequence (that is start the regional sequence
five amino acids before the actual start of the regional sequence and/or end the regional
sequence five amino acids after the actual end of the regional sequence) of the GPCRs.
In order to undertake these motif search, we obtain from UniProt the start and end of the
regional sequence (the N-terminal, extracellular loops, intracellular loops, the seven helices, and
the C-terminal) of the GPCRs. These data were used to split the GPCR sequence into the different
regions (the N-terminal, extracellular loops, intracellular loops, the seven helices, and the Cterminal) using R programming language and were saved as fasta files. After cutting the sequences
into the regions we performed motif search on them using MEME. Motifs that had E-value < 0.1
were retained as significant motifs.
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3.4 STRUCTURAL COMPARISON
In our quest to understand why some ligands bind to GPCRs of three distinct IUPHAR
families, we decided to investigate whether there are some 3D structural similarities across distinct
IUPHAR families that facilitate the binding. To achieve this, we performed pairwise 3D structural
comparisons of the GPCRs that bind to the same ligand and accessed the comparisons based on
the RMSD (root mean square deviation) value of the alignment. The comparisons were done using
Flexible structure AlignmenT by Chaining Aligned fragment pairs allowing Twists (FATCAT)
[Ye & Godzik, 2003; Ye & Godzik, 2004]. We made use of jFATCAT (Java port of FATCAT)
provided by PDB. We performed a rigid FATCAT and a flexible FATCAT. The rigid FATCAT
uses a rigid-body superposition to align the two structures whereas the flexible FATCAT
introduces 'twists' between different parts of the proteins which are superimposed independently
[Prlić et al., 2010; Ye & Godzik, 2004; Ye & Godzik, 2003]. GPCRs that had multiple structures
deposited in PDB, we selected one of their PDB IDs based on their sequence length. That is the
PBD ID with the longest protein sequence of the GPCR or one whose protein sequence length is
closer to the actual GPCR sequence length was chosen for the 3D structural comparison.
3.5 GPCR LIGAND DOCKING
Protein ligand interactions are generally specific, in terms of the ligand involved, and the
location the interaction takes place [Kukol, 2014]. As a result of the location specificity of the
ligand binding sites, we decided to perform molecular docking between the ligands that bind to
GPCRs of three distinct IUPHAR families to find out what they have in common at the binding
sites and what binding residues they share in common at the binding sites. In so doing we imported
3D structures of these GPCRs from PDB and were prepared using Maestro (Schrödinger) protein
preparation wizard [Sastry et al., 2013; Schrödinger Release 2020-4]. The preparation involved
deleting any metal compounds, deleting ligands which are not of interest, and adding and
optimizing hydrogen bonds. The prepared protein was saved having the file extension pdb. These
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were later converted to have the file extension pdbqt using AutoDock tools [Sanner, 1999; Morris
et al., 2009]. To enable this conversion, we added Kollman charges and assigned AD4 type to the
protein to enable AutoDock tools save it as pdbqt file. Before the conversion, we predicted binding
sites of each of the GPCRs using MetaPocket 2.0 [Huang, 2009].
We converted the SMILES (Simplified Molecular Input Line Entry System) of the ligands
into 3D structures using LigPrep [Schrödinger Release 2020-4] and were saved as mol2 file.
Afterwards they were converted to pdbqt files using Open Babel [O’Boyle et al., 2011].
After preparing the proteins and the ligands and having them in the right format, we
performed molecular docking between the ligands that bind to GPCRs of three distinct IUPHAR
families and the GPCRs they bind to. The docking was done using AutoDock Vina [Trott & Olson,
2009]. The results from the docking were viewed using PyMol package in the Schrödinger suite.
Currently, we are working on determining the binding residues and to compare the binding sites
across the different GPCRs of three distinct IUPHAR families that bind to a single ligand.
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Figure 8: Flow Chart of GPCR-ligand docking
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Chapter 4: Results and Discussion
In this chapter we have the overall result on GPCR structure and data collection, conserved
motifs of human GPCR sequences, GPCR structural comparison, and the results obtained by
analyzing the structures have been discussed.
4.1 POPULATING GPCR-PENDB WITH STRUCTURE AND LIGAND DATA
Below are figures of the frequency distribution of the 3D structures we have collected.
There were 800 atomic-level 3D GPCR structures related to 157 distinct GPCRs, of which 106,
27, 14, 1, 0, 9, and 0 are in Class A, B, C, D, E, F, and T2R respectively (see Figure 8). There were
no 3D structures for Class E, however, Class A GPCRs had the most 3D structures on PDB. Figure
9 & 10 shows the frequency distribution by year. Generally, the number of 3D structures of GPCRs
is increasing rapidly by the year. We have added links from GPCR-PEnDB to the PDB structure
files.

Figure 9: Frequency distribution of GPCRs 3D structures
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Figure 10: Frequency distribution of GPCR 3D structures by year

Figure 11: Cumulative frequency distribution of GPCR 3D structures by Year
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In GPCR-PEnDB we collected data on GPCR-ligand interactions which was obtained from
IUPHAR, BindingDB, and GLASS. The data contains a total of 1,061,462 GPCR-ligand
interactions with information on ligands and the binding affinities (Ki, Kd, IC50, EC50, pKB, pKi,
pKd, pIC50, pEC50). In addition, it contains information on ligand’s SMILES (Simplified
Molecular Input Line Entry Specification: is a linear notation for describing chemical structures),
affinity relations, and ligand’s InChIKey (International Chemical Identifier compact hashed code),
potency, activity, inhibition, action (i.e., agonist, full agonist, partial agonist, antagonist, inverse
agonist, biased agonist, neutral, positive, and negative).
4.2 GPCR-LIGAND BINDING
Analysis on the GPCR-ligand binding data revealed that there are ligands that bind to
human GPCRs of multiple IUPHAR families (Table 2). Table 2 shows over 16000 ligands
interacting with human GPCR of two or more IUPHAR families. There were 11 ligands that binds
to human GPCRs of three different IUPHAR families (Table 3 & 4). These 11 ligands had 106
interactions with human GPCRs, involving 69 unique GPCRs. Of the 69 unique GPCRs, 42 had
entries in RCSB PDB. IUPHAR classify three of these ligands as synthetic organic based on their
nature (Table 3). The remaining eight ligands had no entry and classification in IUPHAR.
IUPHAR classify ligands as approved, WHO, synthetic organics, metabolites, natural products,
endogenous peptides, inorganics etc. There were no RCSB PDB entries of GPCR-ligand
interaction of the 11 ligands that bind to human GPCRs of three different IUPHAR families.
Table 2: Frequency distribution of ligands by the number of distinct IUPHAR families they bind
to.
Number of
distinct IUPHAR
families
1
2
3
32

Frequency
98750
16191
11

Table 3: List of the 11 ligands that bind to 3 different IUPHAR families
Ligands InChIKey
XLWJPQQFJNGUPA-UHFFFAOYSA-N
DTZDSNQYNPNCPK-UHFFFAOYSA-N
CLQVVBPDAXJGBV-UHFFFAOYSA-N
AJLFQFYMLRXVHV-UHFFFAOYSA-N
IKSHHOBCJKJKOG-UHFFFAOYSA-N
FQUAFMNPXPXOJE-UHFFFAOYSA-N
MLQFOEOUNIRULR-UHFFFAOYSA-N
YKMSTUDOGGAEJH-UHFFFAOYSA-N
USZPQRMQYJIDII-UHFFFAOYSA-N
BYBLEWFAAKGYCD-UHFFFAOYSA-N
NKOPNLUYOHOGFZ-UHFFFAOYSA-N

Abbreviation
XLWJ
DTZD
CLQV
AJLF
IKSH
FQUA
MLQF
YKMS
USZP
BYBL
NKOP

Compound Class
Synthetic Organic
Synthetic Organic
Synthetic Organic
Not known
Not known
Not known
Not known
Not known
Not known
Not known
Not known

Table 4: Ligands that binds to GPCRs of three IUPHAR families.
Ligands
InChI Key
XLWJ

DTZD

CLQV

AJLF

IKSH

FQUA

GPCR UniProt ID
O75899, Q9UBS5
P16473, P21728, Q6W5P4
P43220, Q03431
P21728
P43220
Q14831
P21453, Q6W5P4
P43220
Q14833
P16473
P43220
Q9NYV8
P16473
Q03431
Q9NYV8
O14842, O14843, O15552, O43194, P07550, P08172,
P11229, P14416, P18825, P24530, P25103, P28222,
P28223, P28335, P29274, P32245, P35367, P35368,
P35372, P37288, P41145, Q5NUL3, Q8IZ08,
Q8TDU9, Q99788
P59536, P59551, Q9NYV7, Q9NYV8, Q9NYW1,
Q9NYW5
33

C
A
B
A
B
C
A
B
C
A
B
T2R
A
B
T2R

Number
in each
Family
2
3
2
1
1
1
2
1
1
1
1
1
1
1
1

A
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T2R

6

IUPHAR
Family

Ligands
InChI Key

MLQF

YKMS

USZP

BYBL

NKOP

GPCR UniProt ID
P47871, P48546
O00222, P41594, Q13255, Q14416, Q14831, Q14832,
Q14833
Q03431
Q6W5P4
P14416, P21917, P35462
P43220
Q14416
P16473
P43220
P41594
P08172, P08173, P08588, P08913, P0DMS8, P11229,
P13945, P14416, P18089, P20309, P21452, P21554,
P21728, P21917, P25021, P25100, P25103, P28223,
P28335, P29274, P30542, P32245, P33032, P35372,
P35462, P41143, P41145, P41595, P41968, P50052,
P50406
O15303
P43220
P43220
Q13255
Q6W5P4

B

Number
in each
Family
2

C

7

B
A
A
B
C
A
B
C

1
1
3
1
1
1
1
1

A
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C
B
B
C
A

1
1
1
1
1

IUPHAR
Family

4.3 CONSERVED MOTIFS OF HUMAN GPCR SEQUENCES
Upon the discovery that there are ligands that bind to human GPCRs of 3 different
IUPHAR families, we set out to find why that happens. These led us to perform motif search on
the sequences to determine whether there are some conserved motifs across different IUPHAR
families. We performed this analysis on the full sequence, regions of the sequence (extracellular
loops, intracellular loops, and the seven transmembrane helices), and modified regions of the
sequence (i.e., adding 5 amino acids either at the beginning or at the end of the regional sequence
or at both ends: this was done only to the extracellular loops). The regions of the GPCR sequences
were labeled 𝐸𝑖, 𝑖 = 1, 2, 3, 4: Extracellular loops; 𝐼𝑖, 𝑖 = 1, 2, 3, 4: Intracellular loops; 𝐻𝑖, 𝑖 =
1, 2, 3, 4, 5, 6, 7: Helices, and 𝐹𝑢𝑙𝑙 : full GPCR sequence. 𝐸1 is the 𝑁 − 𝑡𝑒𝑟𝑚𝑖𝑛𝑎𝑙, and 𝐼4 is the
𝐶 − 𝑡𝑒𝑟𝑚𝑖𝑛𝑎𝑙.
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Below are the results of the motif search using the MEME system. A motif was deemed
significant if E-value < 0.1. This cutoff was chosen to reduce the number of false positive whiles
maintaining many hits. We found motifs that were significant across three IUPHAR families by
the ligands. These motifs were of length as low as 3 and as high as 20 (Table 5). Nevertheless,
there were several significant motifs that were found across two IUPHAR families by the ligands
(Table 8, Appendix A).
Table 5: Human conserved motifs of GPCR sequences across three IUPHAR families
found by the MEME system.
Ligands
InChI
Key

Sequence
Region

CLQV

Full

Full

FQUA

H1

Length of
Region

GPCR
UniProt ID

IUPHAR
Family

371
463
912
380
400
373
471
458
412
466
462
443
494
413
520
453
374
407
418
487
442
361
332
317
318
466
460
346
312
299
307
477
390
330
291
23
25
21
21
20
23
21
24

Q6W5P4
P43220
Q14833
P41145
P35372
Q99788
P28223
P28335
P29274
P08172
P18825
P14416
Q8IZ08
P07550
P35368
O43194
Q8TDU9
P25103
P37288
P35367
P24530
Q5NUL3
P32245
Q9NYV8
P59551
P48546
P11229
O14843
Q9NYW1
Q9NYW5
P59536
P47871
P28222
O15552
Q9NYV7
Q99788
P35372
O43194
Q9NYV8
O14843
P08172
O15552
P37288

A
B
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
T2R
T2R
B
A
A
T2R
T2R
T2R
B
A
A
T2R
A
A
A
T2R
A
A
A
A

Motif Starting
Position in Full
Sequence
196
295
538
65
76
46
80
59
12
29
57
40
109
39
51
36
45
38
57
33
107
46
50
12
23
298
31
20
12
12
12
306
55
128
136
46
76
36
12
20
29
13
57
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Motif

E-value

GCWARWPDDGYW

4.40E-02

VLSLIFLVGILGNVLVIVVI

3.90E-38

VYSLIFVVGILGNVLV

3.00E-32

Ligands
InChI
Key

Sequence
Region

H2

MLQF

E1

YKMS

E2*

Length of
Region

GPCR
UniProt ID

IUPHAR
Family

25
23
21
24
25
26
25
23
23
24
25
23
23
26
23
26
21
21
25
21
21
28
21
25
24
22
24
21
21
22
20
26
26
24
23
25
21
21
26
21
21
22
21
21
22
25
20
21
22
21
23
559
574
549
555
550
556
162
554
52
25
26
28

P35368
P35367
Q5NUL3
P07550
P29274
P28335
P24530
P14416
P11229
P28223
P18825
P25103
O14842
P32245
Q9NYW1
P28222
Q9NYW5
P59536
P47871
Q8TDU9
Q9NYV7
P41145
P08172
P32245
P07550
P28223
P41145
P11229
P35367
P35368
O43194
P28222
P18825
P29274
O14842
P35372
Q8TDU9
Q5NUL3
P24530
Q9NYV7
P59536
P37288
O15552
O14843
P25103
P47871
P48546
Q9NYW5
Q99788
P28335
P14416
P41594
Q13255
Q14416
Q14833
O00222
Q14831
Q03431
Q14832
Q6W5P4
P14416
P35462
P21917

A
A
A
A
A
A
A
A
A
A
A
A
A
A
T2R
A
T2R
T2R
B
A
T2R
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
T2R
T2R
A
A
A
A
B
B
T2R
A
A
A
C
C
C
C
C
C
B
C
A
A
A
A

Motif Starting
Position in Full
Sequence
51
33
46
39
12
59
107
40
31
80
57
38
11
50
12
55
12
12
137
45
5
65
62
83
72
113
98
64
66
84
72
88
90
45
45
109
80
78
140
49
48
90
48
54
71
177
173
48
78
92
73
176
189
169
183
180
183
61
175
43
105
101
106
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Motif

E-value

JVSLALADLLVA

5.90E-47

SPDLSDK

2.00E-02

WKFSRAVCD

2.80E-04

Ligands
InChI
Key

Motif Starting
Position in Full
Sequence
36
P43220
B
208
21
Q14416
C
630
*
We start the region 5 amino acids before and ended 5 amino acids after E2
Sequence
Region

Length of
Region

GPCR
UniProt ID

IUPHAR
Family

Motif

E-value

4.4 RESULT OF GPCR STRUCTURAL COMPARISON
The presence of conversed motifs across the different IUPHAR families informs our
decision to compare the 3D structures of the human GPCRs that bind to the same ligand. This was
to ascertain whether there are 3D structural similarities either by regions of the GPCRs or the entire
GPCRs. We observed that comparisons are often done on the entire GPCRs structures if the
GPCRs involved are from the same IUPHAR family, whereas regional comparisons are often done
when the GPCRs involved are from different IUPHAR family. Table 6 shows the results of the 3D
structural comparisons. We performed two types of comparisons, namely, FATCAT-flexible (Flex
in Table 6, introduces 'twists' between different parts of the proteins which are superimposed
independently) and FATCAT-rigid (Rigid in Table 6, which uses a rigid-body superposition to
align the two structures). FATCAT means Flexible structure AlignmenT by Chaining Aligned
fragment pairs allowing Twists [Ye & Godzik, 2003; Ye & Godzik, 2004].
In the column ‘GPCR UniProt ID’ of Table 6, for example P16473.A, the characters before
the ‘.’ represents the Uniprot ID of the GPCR, whereas the character after the ‘.’ represents the
IUPHAR families. Similarly, in the column ‘PDB ID’ of Table 6, for example 3G04.C, the
characters before the ‘.’ represents the PDB ID of the GPCR, whereas the character after the ‘.’
represents the chain ID. The chain IDs were chosen based on the length of the sequence, i.e., the
chain that have the longest sequence was chosen for the comparison.
We observed that not only did the GPCRs shared conversed motifs but also, shared some
3D structural similarities (Table 6, smaller RMSD value means higher 3D structural similarities).
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Table 6: Pairwise structural comparison of human GPCR using jFATCAT (Java port of
FATCAT).
Ligands
InChI
Key

XLWJ

DTZD
CLQV
AJLF
IKSH
NKOP

USZP

GPCR
UniProt ID

PDB ID

P16473.A,
P43220.B
P16473.A,
Q03431.B
P16473.A,
Q9UBS5.C
P43220.B,
Q03431.B
P43220.B,
Q9UBS5.C
Q03431.B,
Q9UBS5.C
O75899.C,
P16473.A
O75899.C,
P43220.B
O75899.C,
Q03431.B
O75899.C,
Q9UBS5.C
P43220.C,
Q14831.C
P21453.A,
P43220.B
P16473.A,
P43220.B
P16473.A,
Q03431.B
P43220.B,
Q13255.C
P16473.A,
P43220.B
P16473.A,
P41594.C
P43220.B,
P41594.C

3G04.C,
6B3J.R
3G04.C,
6FJ3.A
3G04.C,
7C7S.A
6B3J.R,
6FJ3.A
6B3J.R,
7C7S.A
6FJ3.A,
7C7S.A
6W2X.B,
3G04.C
6W2X.B,
6B3J.R
6W2X.B,
6FJ3.A
6W2X.B,
7C7S.A
6B3J.R,
5C5C.A
3V2Y.A,
6B3J.R
3G04.C,
6B3J.R
3G04.C,
6FJ3.A
6B3J.R,
3KS9.A
3G04.C,
6B3J.R
3G04.C,
6N4X.A
6B3J.R,
6N4X.A

Probability

RMSD

Sequence
Identity
(%)

Sequence
Similarity
(%)

Flex

Rigid

Flex

Rigid

Flex

Rigid

Flex

Rigid

9.89e-01

9.69e-01

2.86

3.70

6

5

15

14

9.39e-01

8.86e-01

2.98

4.66

5

6

12

15

9.13e-01

8.7e-01

3.14

6.07

3

5

12

13

5.70e-08

7.37e-10

2.89

3.02

19

21

30

31

1.33e-03

1.72e-04

3.69

5.68

8

3

19

12

9.44e-03

3.44e-03

4.25

7.03

5

3

14

8

9.38e-01

8.97e-01

3.16

6.04

3

6

12

20

7.87e-04

2.09e-04

3.39

6.07

6

3

16

11

4.60e-03

2.52e-03

3.20

4.60

5

3

14

11

0

0

3.69

3.95

35

32

56

52

1.57e-01

3.70e-01

3.35

8.36

5

2

13

6

3.10e-05

2.26e-05

2.97

5.41

7

3

20

11

9.89e-01

9.69e-01

2.86

3.70

6

5

15

14

9.39e-01

8.86e-01

2.98

4.66

5

6

12

15

3.65e-01

3.64e-01

6.71

7.73

4

3

11

10

9.89e-01

9.69e-01

2.86

3.70

6

5

15

14

7.71e-01

8.12e-01

3.39

7.49

4

3

10

9

3.83e-01

4.71e-01

6.37

11.74

5

2

12

7
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Chapter 5: Conclusion and Future Work
5.1 CONCLUSION BASED ON RESULTS TO DATE
Our exploratory data analyses have shown that there are ligands that bind across two or
more distinct GPCR IUPHAR families. Those GPCRs involved were found in many cases to share
a conserved sequence motif. Also, these GPCRs are either similar in their 3D structure as a whole
or share regional similarities in their 3D structures. This suggests possibilities for predicting GPCR
ligand binding through the integration of 3D structural features with sequence features of GPCRs.
5.2 FUTURE RESEARCH GOALS AND PROPOSED APPROACHES
As stated in Section 1.4, the goal of my PhD research is to develop a computational method
to predict what ligands will bind to a given GPCR with experimentally determined or
computationally predicted structure. The ultimate aim is to establish an integrated prediction tool
that combine sequence and structural features to give reliable information for GPCR-ligand
binding in general. In order to achieve these goals, I have integrated some available GPCR ligand
interaction data into GPCR-PEn and identified 3D structural and sequence features that best
characterize GPCR ligand binding within families of GPCRs and across families of GPCRs. My
PhD dissertation will focus on investigating those ligands that bind to GPCRs of two or more
IUPHAR families, in order to help shed light on their biological nature as well as clinical purposes
in developing better therapeutic drugs for various diseases.
The specific aims are:
1. Determine the classification, 3D structure and binding pockets for any given GPCR. For a
given query GPCR protein sequence Q, we can apply existing tools such as multinomial
logistic regression and multilayer perceptron [Ayivor et al., 2020] to make full prediction of
the GPCR’s classification, including family, subfamily, sub-subfamily, and subtype under the
IUPHAR system. These algorithms are available within the GPCR-PEn webserver. If the 3D
structure for Q is already reported in PDB, we can directly use the information. Otherwise, we
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can computationally predict its 3D structure by applying RaptorX [Wang et al., 2016], which
has been used previously by our group to predict GPCR 3D structures [Munoz et al., 2017].
We will also explore other established structure prediction tools such as I-TASSER [Zhang,
2007] and Quark [Xu & Zhang, 2012] to compare prediction results. For predicting binding
pockets, the MetaPocket 2.0 [Huang, 2009] webserver, which provides a consensus result
combined from several different methods, will be used. We will take the tools they are using
and incorporate into GPCR-Pen.
2. Based on the closest GPCRs to Q by its classification, identify the possible ligands and
determine if the ligands can bind to other GPCR families. We will determine the characteristics
underlying the binding of the same ligand to GPCRs of same and different families, that is but
not limited to the binding residues, binding pocket structural similarities, amino acid motif
sequence of GPCRs around the binding site and the structure of the ligand. The information
collected above will be used to derive sequence and structural features. Based on the features
identified and other features obtained from literature which includes Gasteiger positive and
negative charges, hydrogen bond donor and acceptor, aromatic, hydrophobic, hub and cycle
structures of ligands and amino acid motif sequences of GPCRs (see Section 2.3), we will
design an integrated computational algorithm, using a combination of statistical and machine
learning, to identify possible ligands for Q. Additionally, we will classify GPCRs based on
binding pocket similarities and identify which of the categories the new GPCR belongs. Based
on this classification we will identify more ligands that bind to that category. We then use the
algorithm developed to identify possible ligands that might bind to the Q.
3. Perform docking of the possible ligands to Q and obtain the ligand binding poses and determine
binding affinities. We can apply existing tools such as AutoDock Vina [Trott & Olson, 2009]
to perform docking to determine the ligand binding pose using the 3D structure and the binding
affinities. To do this we will import 3D structures of these GPCRs from PDB (if they exist) or
use their predicted 3D structures obtained with RaptorX [Wang et al., 2016] and prepare them
using Maestro (Schrödinger) protein preparation wizard [Sastry et al., 2013; Schrödinger
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Release 2020-4] for docking. The preparation will involve deleting any ligands which are not
of interest, add and optimize hydrogen bonds, and add the appropriate Kollman charges using
AutoDock tools [Morris et al., 2009]. Additionally, 3D structures of the ligands will be
imported from PDB (if they exist) or we will convert their SMILES (Simplified Molecular
Input Line Entry System) into 3D structures using LigPrep [Schrödinger Release 2020-4].
Afterwards we will perform docking of the ligands to Q and obtain the ligands poses and
binding affinities. Top ligands with best binding affinities will be selected as possible ligands
that will bind to Q for wet lab experiments.
4. Implement the designed computational approach and integrate the developed software tools to
and GPCR ligand binding information to GPCR-PEn for dissemination. Once we have decided
on what the final integrated algorithm is, we will implement it using Python, along with Propy
[Cao et al., 2013], R packages, and other newly developed codes to extract relevant structural
and physiochemical features (e.g., autocorrelation, quasi-sequence order, pseudo-amino acid
composition) for characterizing the GPCR ligand binding. After testing, this prediction
program will be added to the GPCR-Pen web server by means of Webpy to build a fully
functional web application that can be freely accessed by the scientific community. I also plan
to deposit the source code of my programs to GitHub with the goal that it can be downloaded
and modified by other computational scientists for further improvements or different
applications. It is anticipated the various data about GPCRs, and their ligands will be collected
for the development and testing of the computational algorithms. During this process, I will
also pay attention to gathering useful biological and clinical information (e.g., whether a ligand
is naturally occurring or synthetic, whether it is used for treatment of certain diseases, etc.). I
will collaborate with other members of our research group to incorporate such information into
the GPCR-PEn database.
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5.3 EXPECTED RESULTS AND POSSIBLE PITFALLS
Computational prediction of GPCR ligand binding has become a convincing option to high
throughput screening and other experimental approaches during the beginning phases of ligand
discovery. These predictions are cost-efficient and can be important aides for planning wet lab
experiments to help elucidate signaling pathways and expedite drug discovery.
For specific aim 1, we expect to identify the best combination of classification tool and 3D
structural prediction tool that produces the best result when used with our approach. Seo et al.,
(2018) using hub and cycle structures of ligands and amino acid motif sequences of GPCRs
reported a prediction accuracy of 65.1% for GPCRs that do not have binding ligands provided in
the GLASS database and predicted ligands that may bind to them. For specific aim 2 and 3, we
anticipate that our approach will increase the overall prediction accuracies to about 90%. Once we
have decided on what the final integrated algorithm, we anticipate that the analyses will be
computationally intensive especially when it is opened to the public. As a result, we may need to
make arrangements with the UTEP Higher Performance Computing or Texas advance computing
center (TACC) to allow us to use their equipment (specific aim 4).
Also, we anticipate that there may be improvements in the tools for 3D structure prediction
and GPCR classification, and our current choice of prediction tools may be outperformed by newer
ones. For instance, AlphaFold 2 is an artificial intelligence program developed by Google's
DeepMind, for predicting protein 3D structure achieved a level of accuracy much higher than any
other computational method [Heaven, 2020]. For this reason, I will be monitoring improvements
in these areas in order to keep our algorithm up to date with latest developments.
5.4 TIMELINE
Table 7 on the next page shows the tentative timeline for the research goals to be
completed.
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Table 7: Timeline for completion of research goals
Date
January 2021 – May 2021

Tasks to complete
Finalize the compilation of the ligands that bind to
GPCRs of two or more IUPHAR families for upcoming
investigation
Determine the classification, 3D structure and binding
pockets for any given GPCR (specific aim 1).
Identifying 3D structural features and sequence features
(specific aim 2).

June 2021 – August 2021

Design an integrated computational algorithm to
identify possible ligands that may bind to a GPCR
(specific aim 2).
Perform docking of the possible ligands to the GPCR
and obtain the ligand binding pose and binding affinities
(specific aim 3).

September 2021 – December 2021

Software implementation and incorporation with GPCRPen for public distribution (specific aim 4)

January 2022 – May 2022

Finalize Ph.D. dissertation and prepare for defense.
Prepare manuscript for journal publication.
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Appendix
Appendix A
Table 8: Human conserved motifs of GPCR sequences across two IUPHAR families found by
the MEME system

Ligands
InChI Key
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FQUA

Sequence
Region

I4

I2

I4

Length of
Region

GPCR
UniProt ID

IUPHAR
Family

Motif Starting
Position in Full
Sequence

12

P14416

A

432
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406
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427
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P37288
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148
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148
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Sequence
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Motif Starting
Position in Full
Sequence
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P14416
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O14842
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O14842

A
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A
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A
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C
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A
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A
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21
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B
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B

451
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A
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P43220

B
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C
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P43220

B

356

1212

P41594

C

37
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P35367

A

452

25

P28335

A

337
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P28223

A
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23
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A

340

61

Motif

E-value
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1.50E-06
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5.50E-02

DRYHAITYPM
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QHQWD

4.20E-02
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5.50E-05
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Sequence
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Length of
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Position in Full
Sequence

22

P47871

B
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25

P48546

B

361

23

P18825

A

408

24

P11229

A

391

35

P13945

A

185

36

P08588

A

205

25

P43220

B

286

561

Q14831

C

586

121

P43220

B

87

Motif

E-value

EARRCYNDPKCCDFASNMPY

2.40E-03

WHLPWA

8.10E-01

*

We start the region 5 amino acids before and ended 5 amino acids after E3, and E4. Ended 5 amino acids after E1

Appendix B: Cumulative frequency distribution of GPCR 3D structures by Year
PDB_ID_Date <-read.csv("PDB_ID_Date.csv",header = T, fill=TRUE, stringsAsFactors = F,
colClasses = c('character','Date'))
PDB_ID_Date$Rel..Date <- substring(PDB_ID_Date$Rel..Date,1,4)
dim(PDB_ID_Date)
str(PDB_ID_Date)
library(lattice)
barchart(PDB_ID_Date$Rel..Date, ylab = "Frequency", xlab = "Year", horizontal = F)
cumFreq <- ftable(PDB_ID_Date$Rel..Date)
l <- as.data.frame(cumFreq)
k <- cumsum(l$Freq)
l$Freq <- k
barchart(Freq ~ Var1, data = l, ylab = "Frequency", xlab = "Year", horizontal = F)
Appendix C: Frequency distribution of GPCRs 3D structures
pcrPDB <-read.csv("108 Unique GPCRcopy.csv", sep = ',', header = T, fill=TRUE,
stringsAsFactors = F)
colnames(gpcrPDB)
colnames(gpcrPDB)[which(names(gpcrPDB) == "Uniprot.AF8.ID")] <- "Uniprot_ID"
GPCR_Pen <-read.csv("gpcrpendb.csv", sep = ',', header = T, fill=TRUE, stringsAsFactors = F)
colnames(GPCR_Pen)
colnames(GPCR_Pen)[which(names(GPCR_Pen) == "IUPHAR_.family.")] <- "IUPHAR_family"
# merging data to have GPCR families
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gpcrPDBfinal <- merge(GPCR_Pen, gpcrPDB, by.x = "Uniprot_ID", all.x = T)
head(gpcrPDBfinal)
# get the ones that have 3D structures
gpcrPDBfinal <- gpcrPDBfinal[!is.na(gpcrPDBfinal$Freq),]
# getting the total number in each family or class
gpcrPDBfinal1 <- aggregate(gpcrPDBfinal$Freq, by = list(gpcrPDBfinal$IUPHAR_family),
FUN = "sum")
gpcrPDBfinal1[c(6,7),1] <- c("Class E", "Class T2R")
gpcrPDBfinal1[c(6,7),2] <- c(NA,NA)
ord <- order(gpcrPDBfinal1$Group.1)
gpcrPDBfinal1 <- gpcrPDBfinal1[ord,]
colnames(gpcrPDBfinal1)[which(names(gpcrPDBfinal1) == "Group.1")] <- "IUPHAR_family"
colnames(gpcrPDBfinal1)[which(names(gpcrPDBfinal1) == "x")] <- "Frequency"
library(plyr)
# getting the number of unique GPCR by Class
gpcrPDBfinal2 <- count(gpcrPDBfinal, vars = "IUPHAR_family")
gpcrPDBfinal2[c(6,7),1] <- c("Class E", "Class T2R")
gpcrPDBfinal2[c(6,7),2] <- c(NA,NA)
ord <- order(gpcrPDBfinal2$IUPHAR_family)
gpcrPDBfinal2 <- gpcrPDBfinal2[ord,]
colnames(gpcrPDBfinal2)[which(names(gpcrPDBfinal2) == "freq")] <- "Unique_ID"
# creating data set from gpcrPDBfinal1 and gpcrPDBfinal2
gpcrPDBfinal3 <-merge(gpcrPDBfinal1, gpcrPDBfinal2, by = "IUPHAR_family")
library(lattice)
barchart(Frequency+Unique_ID~IUPHAR_family, data = gpcrPDBfinal3,
ylab = "Frequency", xlab = "IUPHAR Family",
auto.key = list(text= c("Entries", "Unique ID")))
Appendix D: Finding unique GPCRs on PDB
GPCR_Pen <-read.csv("GPCR_Pen.txt",header = T, fill=TRUE, stringsAsFactors = F)
GPCR_Pen <-as.data.frame(GPCR_Pen)
rscbPDBgpcr <-read.csv("Finding Unique GPCR_2020.csv",header = T, fill=T, sep = ",",
stringsAsFactors = F, blank.lines.skip = F)
rscbPDBgpcr <- rscbPDBgpcr[-c(2447),]
head(rscbPDBgpcr)
str(rscbPDBgpcr)
rscbPDBgpcr$ID1[rscbPDBgpcr$ID1 == ""] <- NA
rscbPDBgpcr$ID2[rscbPDBgpcr$ID2 == ""] <- NA
rscbPDBgpcr$ID3[rscbPDBgpcr$ID3 == ""] <- NA
63

rscbPDBgpcr$ID1 <-as.vector(rscbPDBgpcr$ID1)
rscbPDBgpcr$ID2 <-as.vector(rscbPDBgpcr$ID2)
rscbPDBgpcr$ID3 <-as.vector(rscbPDBgpcr$ID3)
rscbPDBgpcrFinal <-append(rscbPDBgpcr$ID1,c(rscbPDBgpcr$ID2,rscbPDBgpcr$ID3))
rscbPDBgpcrFinal <- rscbPDBgpcrFinal[!is.na(rscbPDBgpcrFinal)]
rscbPDBgpcrFinal <- as.data.frame(rscbPDBgpcrFinal)
colnames(rscbPDBgpcrFinal)[which(names(rscbPDBgpcrFinal) == "rscbPDBgpcrFinal")] <"Uniprot_ID"
dim(rscbPDBgpcrFinal)
rscbPDBgpcrUnique <-intersect(as.vector(rscbPDBgpcrFinal$Uniprot_ID),
as.vector(GPCR_Pen$ID))
length(rscbPDBgpcrUnique)
write.csv(rscbPDBgpcrUnique, file = "/home/owusu/Desktop/GPCR/108 Unique GPCR.csv")
Appendix E: Processing IUPHAR data
nteractions <- read.csv(file = "interactions.csv", sep = ',', fill = F, stringsAsFactors = F,
header = T)
ligands <- read.csv(file = "ligands.csv", sep = ',',
fill = F, stringsAsFactors = F, header = T)
iuphar <- merge(interactions, ligands, by.x = "ligand_id", by.y = "Ligand.id")
write.csv(iuphar, file = "/home/owusu/Desktop/GPCR/Ligand_GPCR/IUPHAR/iupharData.csv")
# done next day
iupharData <- read.csv(file = "iupharData.csv", sep = ',', fill = F, stringsAsFactors = F,
header = T)
colnames(iupharData)
iupharData <- iupharData[, c(6,15,19,20,26,27,28,29,34,49,52,53,54)]
write.csv(iupharData, file =
"/home/owusu/Desktop/GPCR/Ligand_GPCR/IUPHAR/iupharData.csv",
row.names = F)
Appendix F: Processing GPCRdb data
file.names <- read.csv(file = "list.txt", sep = "\t", fill = F, stringsAsFactors = F,
header = T)
library(xlsx)
N <- NROW(file.names)
residuesGPCRdb <- data.frame(stringsAsFactors = F)
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for (i in 1:N) {
PDB.ID <- substr(file.names[i,], 18, 21)
file.name <- paste("Interaction_data_",PDB.ID,".xlsx", sep = "")
dat <- suppressWarnings(read.xlsx(file = file.name, sheetIndex = 1))
if(NROW(dat) != 0 | NCOL(dat) != 0){
dat <- cbind(dat, PDB.ID=PDB.ID, stringsAsFactors = F)
residuesGPCRdb <- rbind(residuesGPCRdb, dat)
}
}
# write the final data a csv file
write.table(residuesGPCRdb, sep = "\t",
file = "/home/owusu/Desktop/GPCR/final_data/residuesGPCRdb.csv", row.names=FALSE)
Appendix G: Processing BindingDB data
bindingDb.1 <- read.csv(file = "O00222.tsv", sep = '\t',
fill = F, stringsAsFactors = F, header = T)
bindingDb.1 <- bindingDb.1[-c(1:7), ]
# set directory
setwd("/home/owusu/Desktop/GPCR/Ligand_GPCR/bindingDb/BindingDB_All_2020m3")
bindingDb.all <- read.csv(file = "BindingDB_All.tsv", sep = '\t', skip = 1,
fill = T, stringsAsFactors = F, header = F)
colnames(bindingDb.all)
colnames(bindingDb.1)
bindingDb.all <- bindingDb.all[, c(2,3,4,6,9,10,11,12,27,28,33,39,42)]
names(bindingDb.all) <- c("SMILES","InChI","InChIKey","BindingDB.Ligand.Name",
"Ki.nM","IC50.nM","Kd.nM","EC50.nM","Ligand.HET.ID.in.PDB",
"PDB.ID.for.Ligand.Target.Complex","DrugBank.ID.of.Ligand","PDB.ID.of.Target.Chain",
"UniProt.ID.of.Target")
write.csv(bindingDb.all,
file =
"/home/owusu/Desktop/GPCR/Ligand_GPCR/bindingDb/BindingDB_All_2020m3/bindingDb.all.
csv", row.names = FALSE)
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Appendix H: Combine data sets
# get data
GPCR_Pen <-read.csv("GPCR_Pen.txt",header = T, fill=TRUE, stringsAsFactors = F)
GPCR_Pen <-as.data.frame(GPCR_Pen)
# set directory
setwd("/home/owusu/Desktop/GPCR/Ligand_GPCR/bindingDb/BindingDB_All_2020m3")
bindingDb.all <- read.csv(file = "bindingDb.all.csv", sep = ',',
fill = T, stringsAsFactors = F, header = T)
# set directory
setwd("/home/owusu/Desktop/GPCR/Ligand_GPCR/IUPHAR")
iupharData <- read.csv(file = "iupharData.csv", sep = ',', fill = F, stringsAsFactors = F,
header = T)
# set directory
setwd("/home/owusu/Desktop/GPCR/Ligand_GPCR/glass")
glassData <- read.csv(file = "interactions_total.tsv", sep = '\t', fill = TRUE, stringsAsFactors = F,
header = T)
glassData <- glassData[, -c(7,8,9)]
# set directory
setwd("/home/owusu/Desktop/GPCR/final_data")
colnames(bindingDb.all)
colnames(iupharData)
colnames(glassData)
colnames(iupharData)[9] <- c("affinity_relation")
# check for the GPCRs
cond <- bindingDb.all$UniProt.ID.of.Target %in% GPCR_Pen$ID
sum(cond)
cond1 <- glassData$UniProt.ID %in% GPCR_Pen$ID
sum(cond1)
cond2 <- glassData$UniProt.ID %in% bindingDb.all$UniProt.ID.of.Target
sum(cond2)
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cond3 <- bindingDb.all$UniProt.ID.of.Target %in% glassData$UniProt.ID
sum(cond3)
bindingDb.all <- bindingDb.all[cond, ]
# get them to have the same columns
names(bindingDb.all) <- c("SMILES","InChI","InChIKey","ligand",
"Ki.nM","IC50.nM","Kd.nM","EC50.nM","Ligand.HET.ID.in.PDB",
"PDB.ID.for.Ligand.Target.Complex","DrugBank.ID.of.Ligand","PDB.ID.of.Target.Chain",
"UniProt.ID.of.Target")
bindingDbNewNames <- c("type","action","affinity_units","affinity_high","affinity_median",
"affinity_low","Parameter","Value","Unit","affinity_relation","IUPAC.name")
bindingDb.all[, bindingDbNewNames] <- NA
bindingDb.all[["Database.Source"]] <- "BindingDB"
glassNewNames <- c("ligand","Ki.nM","IC50.nM","Kd.nM","EC50.nM","Ligand.HET.ID.in.PDB",
"PDB.ID.for.Ligand.Target.Complex","DrugBank.ID.of.Ligand","PDB.ID.of.Target.Chain",
"type","action","affinity_units","affinity_high",
"affinity_median","affinity_low","affinity_relation","IUPAC.name","SMILES","InChI")
glassData[, glassNewNames] <- NA
colnames(glassData)
names(glassData)[1:2] <- c("UniProt.ID.of.Target","InChIKey")
iupharNewNames <- c("Ki.nM","IC50.nM","Kd.nM","EC50.nM","Ligand.HET.ID.in.PDB",
"PDB.ID.for.Ligand.Target.Complex","DrugBank.ID.of.Ligand","PDB.ID.of.Target.Chain",
"Parameter","Value","Unit")
iupharData[, iupharNewNames] <- NA
iupharData[["Database.Source"]] <- "IUPHAR"
colnames(iupharData)
names(iupharData)[1] <- c("UniProt.ID.of.Target")
# check the if they have same columns
colnames(bindingDb.all)
colnames(iupharData)
colnames(glassData)
# get the columns in the same order
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ord <- c(13,4,1,2,3,24,14,15,5,6,7,8,16,19,18,17,20,21,22,23,9,10,11,12,25)
ord1 <- c(1,2,11,13,12,10,3,4,14,15,16,17,5,8,7,6,22,23,24,9,18,19,20,21,25)
ord2 <- c(1,7,24,25,2,23,16,17,8,9,10,11,18,21,20,19,3,4,5,22,12,13,14,15,6)
bindingDb.all <- bindingDb.all[, ord]
iupharData <- iupharData[, ord1]
glassData <- glassData[, ord2]
glassData$Database.Source <- "GLASS"
# append them together
Final_Data <- rbind(iupharData, bindingDb.all)
Final_Data <- rbind(Final_Data, glassData)
cond <- Final_Data$UniProt.ID.of.Target == ""
sum(cond)
Final_Data <- Final_Data[!cond, ]
# check Uniprot ID's and fix it
library(stringr)
text1 <- str_length(Final_Data$UniProt.ID.of.Target)
cond <- text1 > 6
sum(cond)
gpcr_position <- which(cond == T, arr.ind = T)
gpcrList <- Final_Data$UniProt.ID.of.Target[cond]
gpcrList[1]
gpcrList1 <- strsplit(gpcrList,split='|', fixed=T)
newData <- data.frame(stringsAsFactors = F)
n <- 1
for (m in gpcr_position) {
glist <- data.frame(ID = gpcrList1[[n]], stringsAsFactors = F)
glist <- cbind(glist, Final_Data[m,], stringsAsFactors = F)
glist$UniProt.ID.of.Target <- glist$ID
newData <- rbind(newData, glist)
n <- n + 1
}
head(newData)
newData <- newData[, -c(1)]
suppressPackageStartupMessages(library(dplyr))
newData <- distinct(newData)
Final_Data <- Final_Data[!cond,]
Final_Data <- rbind(Final_Data, newData)
# keep only distinct rows
Final_Data <- distinct(Final_Data)
# check and keep only GPCR data
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cond <- Final_Data$UniProt.ID.of.Target %in% GPCR_Pen$ID
sum(cond)
Final_Data <- Final_Data[cond,]
# ligands with no InChIKey
cond <- is.na(Final_Data$InChIKey)
sum(cond)
Final_Data1 <- Final_Data[cond, ]
# write the final data a csv file
write.table(Final_Data, sep = "\t",
file = "/home/owusu/Desktop/GPCR/final_data/Final_Data.csv", row.names=FALSE)
Appendix I: Restructure newData set to have all affinity parameters on a ligand-GPCR on
one column
newData <- read.csv(file = "Final_Data.csv", sep = '\t',
fill = F, stringsAsFactors = F, header = T)
# subset newData for data from glass, iuphar, bindingdb
cond <- newData$Database.Source == "GLASS"
sub.glass <- newData[cond,]
cond <- newData$Database.Source == "IUPHAR"
sub.iuphar <- newData[cond,]
cond <- newData$Database.Source == "BindingDB"
sub.bindingdb <- newData[cond,]
# remove duplicates in glass data, iuphar, and bindingdb
suppressPackageStartupMessages(library(dplyr))
sub.glass <- distinct(sub.glass)
sub.iuphar <- distinct(sub.iuphar)
sub.bindingdb <- distinct(sub.bindingdb)
# keep only Set 1: Top 7 highest (Ki, IC50, Potency, EC50, Inhibition, Activity, Kd, pKB) of
parameter
cond <- (sub.glass$Parameter == "Ki")|(sub.glass$Parameter == "IC50")|
(sub.glass$Parameter == "Potency")|(sub.glass$Parameter == "EC50")|
(sub.glass$Parameter == "Inhibition")|(sub.glass$Parameter == "Activity")|
(sub.glass$Parameter == "Kd")|(sub.glass$Parameter == "pKB")
sub.glass <- sub.glass[cond,]
# keep only pKi, pIC50, pKd, pEC50 of affinity_units
cond <- (sub.iuphar$affinity_units=="pKi")|(sub.iuphar$affinity_units=="pIC50")|
(sub.iuphar$affinity_units=="pKd")|(sub.iuphar$affinity_units=="pEC50")|
(sub.iuphar$affinity_units=="pKB")
sub.iuphar <- sub.iuphar[cond,]
# keep units nM(Ki, Kd, IC50, EC50, Potency), %(Activity, Inhibition), -(pKB)
69

cond <- (sub.glass$Unit == "nM")|(sub.glass$Unit == "%")|(sub.glass$Unit == "-")
sub.glass <- sub.glass[cond,]
#### Glass
# create the variables Activity, Inhibition, Potency, pKB, pKi, pIC50, pEC50, pKd
var.names <- c("Activity.%","Inhibition.%","Potency.nM","pKB","pKi","pIC50","pEC50","pKd",
"pEC50.low","pEC50.high","pIC50.low","pIC50.high","pKB.low","pKB.high",
"pKd.low","pKd.high","pKi.low","pKi.high")
sub.glass[,var.names] <- NA
indx <- c(26,27,28,9,10,12,11,29)
parameters <- c("Activity", "Inhibition", "Potency", "Ki", "IC50", "EC50", "Kd", "pKB")
for (i in 1:length(parameters)){
cond <- which((sub.glass$Parameter == parameters[i]), arr.ind = T)
sub.glass[cond,indx[i]] <- sub.glass$Value[cond]
}
#### IUPHAR
sub.iuphar[,var.names] <- NA
parameters <- c("pKB","pEC50","pIC50","pKd","pKi")
indx <- c(29,32,31,33,30)
indx.1 <- c(38,34,36,40,42)
indx.2 <- c(39,35,37,41,43)
for (i in 1:length(parameters)){
cond <- which((sub.iuphar$affinity_units == parameters[i]), arr.ind = T)
sub.iuphar[cond,indx[i]] <- sub.iuphar$affinity_median[cond]
sub.iuphar[cond,indx.1[i]] <- sub.iuphar$affinity_low[cond]
sub.iuphar[cond,indx.2[i]] <- sub.iuphar$affinity_high[cond]
}
#### Bindingdb
sub.bindingdb[,var.names] <- NA
# get new data
newData <- rbind(sub.bindingdb,sub.iuphar,sub.glass)
var.nm <- c(1,5,2,3,4,6,7,8,9,10,11,12,29,30,31,32,33,34,35,36,37,38,39,
40,41,42,43,28,26,27,20,21,23,22,25)
newData <- newData[, var.nm]
# make some variables numeric
for (i in 9:30) {
newData[,i] <- as.numeric(newData[,i])
}
# write data to csv file
write.table(newData, sep = "\t",
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file = "/Users/kwabena/Reseach/GPCR/final_data/gpcr_Ligand_data_final.csv",
row.names=FALSE)
Appendix J: Clean Symbols from data
Final_Data <- read.csv(file = "Final_Data.csv", sep = "\t", fill = F, stringsAsFactors = F,
header = T, na.strings=c("","NA"," ","N/A"))
library(stringr)
### Ki.nM do for "<" , ">", "="
symb <- str_which(Final_Data$Ki.nM, ">")
ki <- Final_Data$Ki.nM[symb]
ki <- unlist(ki)
ki_List <- strsplit(ki,split='>', fixed=T)
ki.val <- data.frame(stringsAsFactors = F)
for (q in 1:length(ki_List)) {
ki.val.list <- data.frame(val = ki_List[[q]][2], stringsAsFactors = F)
ki.val <- rbind(ki.val, ki.val.list, stringsAsFactors = F)
}
ki.val <- as.vector(unlist(ki.val))
Final_Data$Ki.nM[symb] <- ki.val
Final_Data$affinity_relation[symb] <- ">"
rm(ki_List, ki.val, ki.val.list,symb,ki,q)
### Kd.nM do for "<" , ">", "="
symb <- str_which(Final_Data$Kd.nM, "=")
kd <- Final_Data$Kd.nM[symb]
kd <- unlist(kd)
kd_List <- strsplit(kd,split='=', fixed=T)
kd.val <- data.frame(stringsAsFactors = F)
for (q in 1:length(kd_List)) {
kd.val.list <- data.frame(val = kd_List[[q]][2], stringsAsFactors = F)
kd.val <- rbind(kd.val, kd.val.list, stringsAsFactors = F)
}
kd.val <- as.vector(unlist(kd.val))
Final_Data$Kd.nM[symb] <- kd.val
Final_Data$affinity_relation[symb] <- "="
rm(kd_List, kd.val, kd.val.list,symb,kd,q)
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### IC50.nM do for "<" , ">"
symb <- str_which(Final_Data$IC50.nM, "=")
IC50 <- Final_Data$IC50.nM[symb]
IC50 <- unlist(IC50)
IC50_List <- strsplit(IC50,split='=', fixed=T)
IC50.val <- data.frame(stringsAsFactors = F)
for (q in 1:length(IC50_List)) {
IC50.val.list <- data.frame(val = IC50_List[[q]][2], stringsAsFactors = F)
IC50.val <- rbind(IC50.val, IC50.val.list, stringsAsFactors = F)
}
IC50.val <- as.vector(unlist(IC50.val))
Final_Data$IC50.nM[symb] <- IC50.val
Final_Data$affinity_relation[symb] <- "="
rm(IC50_List, IC50.val, IC50.val.list,symb,IC50,q)
### EC50.nM do for "<" , ">", "="
symb <- str_which(Final_Data$EC50.nM, "=")
EC50 <- Final_Data$EC50.nM[symb]
EC50 <- unlist(EC50)
EC50_List <- strsplit(EC50,split='=', fixed=T)
EC50.val <- data.frame(stringsAsFactors = F)
for (q in 1:length(EC50_List)) {
EC50.val.list <- data.frame(val = EC50_List[[q]][2], stringsAsFactors = F)
EC50.val <- rbind(EC50.val, EC50.val.list, stringsAsFactors = F)
}
EC50.val <- as.vector(unlist(EC50.val))
Final_Data$EC50.nM[symb] <- EC50.val
Final_Data$affinity_relation[symb] <- "="
rm(EC50_List, EC50.val, EC50.val.list,symb,EC50,q)
### Value do for "<" , ">"
symb <- str_which(Final_Data$Value, "=")
Value <- Final_Data$Value[symb]
Value <- unlist(Value)
Value_List <- strsplit(Value,split='=', fixed=T)
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Value.val <- data.frame(stringsAsFactors = F)
for (q in 1:length(Value_List)) {
Value.val.list <- data.frame(val = Value_List[[q]][2], stringsAsFactors = F)
Value.val <- rbind(Value.val, Value.val.list, stringsAsFactors = F)
}
Value.val <- as.vector(unlist(Value.val))
Final_Data$Value[symb] <- Value.val
Final_Data$affinity_relation[symb] <- "="
rm(Value_List, Value.val, Value.val.list,symb,Value,q)
Final_Data$Ki.nM <- as.numeric(Final_Data$Ki.nM)
Final_Data$Kd.nM <- as.numeric(Final_Data$Kd.nM)
Final_Data$IC50.nM <- as.numeric(Final_Data$IC50.nM)
Final_Data$EC50.nM <- as.numeric(Final_Data$EC50.nM)
Final_Data$Value <- as.numeric(Final_Data$Value)
# write the final data a csv file
write.table(Final_Data, sep = "\t",
file = "/home/owusu/Desktop/GPCR/final_data/Final_Data.csv", row.names=FALSE)
Appendix K: Ligands that bind to multiple Human GPCR
#### Phase One
Final_Data <- read.csv(file = "Final_Data.csv", sep = "\t", fill = F, stringsAsFactors = F,
header = T)
colnames(Final_Data)
ligand_uniq <- as.vector(unique(Final_Data$InChIKey))
l.na <- which(is.na(ligand_uniq), arr.ind = T)
ligand_uniq <- ligand_uniq[-c(l.na)]
ligand_freq <- NULL
for (i in ligand_uniq) {
cond <- Final_Data$InChIKey == i
if (sum(cond, na.rm = T) > 1){
sub <- Final_Data[cond,]
len <- NROW(sub)
gp_uniq <- as.vector(unique(sub$UniProt.ID.of.Target))
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}

}

len_uniq <- length(gp_uniq)
dat <- list(ligand = i, Freq = len, gpcr = gp_uniq, gpUniqFreq = len_uniq)
ligand_freq <- rbind(ligand_freq, dat)

ligand_freq <- as.data.frame(ligand_freq)
ligand_freq$ligand <- as.character(ligand_freq$ligand)
ligand_freq$gpcr <- as.character(ligand_freq$gpcr)
ligand_freq$Freq <- as.numeric(ligand_freq$Freq)
ligand_freq$gpUniqFreq <- as.numeric(ligand_freq$gpUniqFreq)
cond <- ligand_freq$gpcr == ""
ligand_freq <- ligand_freq[!cond,]
ligand_Multi_GPCR <- ligand_freq[, -c(3)]
lig_mult_gpcr_only <- ligand_freq[, 3]
write.csv(ligand_Multi_GPCR, file =
"/export/home/okdankwah/Desktop/Thesis/final_data/ligand_Multi_GPCR.csv",
row.names=FALSE)
write.csv(lig_mult_gpcr_only, file =
"/export/home/okdankwah/Desktop/Thesis/final_data/lig_mult_gpcr_only.txt",
row.names=FALSE)
#### Phase Two
ligand_data1 <- read.csv(file = "lig_mult_gpcr_only.txt", sep = '\t',
fill = F, stringsAsFactors = F, header = T, col.names = "gpcr")
ligand_data2 <- read.csv(file = "ligand_Multi_GPCR.csv", sep = ',',
fill = F, stringsAsFactors = F, header = T)
ligand_data <- cbind(ligand_data2, ligand_data1)
cond <- ligand_data$gpUniqFreq > 1
ligand_data <- ligand_data[cond, ]
rm(list = c("ligand_data1","ligand_data2","cond"))
gpcr_data <- read.csv(file = "gpcrpendb_results_1583529702.49.csv", sep = ',',
fill = F, stringsAsFactors = F, header = T)
library(stringr)
N <- NROW(ligand_data)
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ligand_mult_gpcr_result <- data.frame(stringsAsFactors = F)
for (j in 1:N) {
gpcr <- as.vector(str_split(str_replace_all(ligand_data$gpcr[j],"[()c\",]",""), " ")[[1]])
cond2 <- gpcr_data$ID %in% gpcr
lig.gpcr_data <- gpcr_data[cond2, ]
InChIKey <- ligand_data[j, 1]
InChIKey <- cbind(InChIKey, lig.gpcr_data, stringsAsFactors = F)
ligand_mult_gpcr_result <- rbind(ligand_mult_gpcr_result, InChIKey)
}
# write.csv(ligand_mult_gpcr_result, sep = "\t",
#
file = "/home/owusu/Desktop/GPCR/final_data/ligand_mult_gpcr_result_final.csv",
#
row.names=FALSE)
write.csv(ligand_mult_gpcr_result, sep = "\t",
file =
"/export/home/okdankwah/Desktop/Thesis/final_data/ligand_mult_gpcr_result_final.csv",
row.names=FALSE)
#### Phase Three
ligand_data_mult <- read.csv(file = "ligand_mult_gpcr_result_final.csv", sep = ',',
fill = F, stringsAsFactors = F, header = T)
ligand_data_mult.all <- ligand_data_mult
cond <- ligand_data_mult$Common.name == 'Human'
ligand_data_mult <- ligand_data_mult[cond, ]
ligandID <- as.vector(ligand_data_mult$InChIKey)
len <- length(ligandID)
len
# result <- ligand_data_mult.all[,c(1,12)]
result <- data.frame(stringsAsFactors=FALSE)
for (k in 1:len) {
cond <- ligand_data_mult$InChIKey == ligandID[k]
result <- rbind(result,
ftable(ligand_data_mult[cond,]$InChIKey, ligand_data_mult[cond,]$IUPHAR..family.),
stringsAsFactors=FALSE)
}
# subset the all duplicates in the result_duplicate to capture ligands that binds to multiple class
result_duplicate <- result[duplicated(result$Var1) | duplicated(result$Var1, fromLast=TRUE), ]
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l <- sapply(result_duplicate, is.factor)
result_duplicate[l] <- lapply(result_duplicate[l], as.character)
write.csv(result_duplicate, sep = "\t",
file = "/export/home/okdankwah/Desktop/Thesis/final_data/result_duplicate.csv",
row.names=FALSE)
Appendix L: Analysis of Ligands that bind to multiple Human GPCR data
result_duplicate <- read.csv("result_duplicate.csv", sep = ",",
fill = F, stringsAsFactors = F, header = T)
ligand_data_mult <- read.csv(file = "ligand_mult_gpcr_result_final.csv", sep = ',',
fill = F, stringsAsFactors = F, header = T)
suppressPackageStartupMessages(library(dplyr))
# get unique rows
result_duplicate.uniq <- distinct(result_duplicate)
names(result_duplicate.uniq) <- c("InChIKey","IUPHAR.Family","Number.Unique.GPCRs")
# get data on number of classes each ligand (that binds to multiple gpcrs) binds to
freq_ligMult_class <- table(result_duplicate.uniq$InChIKey)
freq_ligMult_class <- data.frame(freq_ligMult_class, stringsAsFactors=FALSE)
names(freq_ligMult_class) <- c("InChIKey", "Number.Unique.Classes")
l <- sapply(freq_ligMult_class, is.factor)
freq_ligMult_class[l] <- lapply(freq_ligMult_class[l], as.character)
# get the number of ligands that binds multiple gpcr of 1, 2, and 3 classes
freq_ligMult_class.Result <- table(freq_ligMult_class$Number.Unique.Classes)
freq_ligMult_class.Result <- data.frame(freq_ligMult_class.Result, stringsAsFactors=FALSE)
names(freq_ligMult_class.Result) <- c("Number.Unique.Classes", "Frequency")
# number of ligands (that binds to multiple gpcrs) that binds to the different classes
freq_class <- table(result_duplicate.uniq$IUPHAR.Family)
freq_class <- data.frame(freq_class, stringsAsFactors = F)
names(freq_class) <- c("IUPHAR.Family", "Frequency")
# get data on ligands that binds to gpcrs of 3 classes
cond <- freq_ligMult_class$Number.Unique.Classes == 3
sum(cond, na.rm = T)
InChIKey <- freq_ligMult_class$InChIKey[cond]
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cond <- ligand_data_mult$InChIKey %in% InChIKey
sum(cond, na.rm = T)
data_ligMult_class_3 <- ligand_data_mult[cond,]
# get the unique classes
unique(data_ligMult_class_3$IUPHAR..family.)
# write data to csv file
write.table(data_ligMult_class_3, sep = "\t",
file = "/home/owusu/Desktop/GPCR/final_data/data_lig_Mult_3_classes.csv",
row.names=FALSE)
Appendix M: Cuts sequences into extracellular loops, intracellular loops, and helices
library(seqinr)
ligID <- c("FQUAFMNPXPXOJE-UHFFFAOYSA-N","MLQFOEOUNIRULR-UHFFFAOYSAN","YKMSTUDOGGAEJH-UHFFFAOYSA-N",
"USZPQRMQYJIDII-UHFFFAOYSA-N","BYBLEWFAAKGYCD-UHFFFAOYSAN","NKOPNLUYOHOGFZ-UHFFFAOYSA-N",
"AJLFQFYMLRXVHV-UHFFFAOYSA-N","CLQVVBPDAXJGBV-UHFFFAOYSAN","DTZDSNQYNPNCPK-UHFFFAOYSA-N",
"IKSHHOBCJKJKOG-UHFFFAOYSA-N","XLWJPQQFJNGUPA-UHFFFAOYSA-N")
num.ligID <- length(ligID)
for (k in 1:num.ligID) {
# read the positions of the extracellular loops, helices, etc
filName <- paste(ligID[k],"txt", sep = ".")
positn <- read.table(file = filName, header = T, sep = "", stringsAsFactors = F)
# read the fasta file of the gpcrs
fastaName <- paste(ligID[k], "fasta", sep = ".")
fasta <- read.fasta(file = fastaName, seqtype = "AA", as.string = T, whole.header = F,
strip.desc = F)
# get the number of gpcr in fasta file
num.seq <- (NROW(positn))/2
for (j in 3:NCOL(positn)) {
seq.fasta <- NULL
seq.ID <- c()
# row begin = i+(i-1), row end = i+((i+1)-1), i = 1:num.seq, rows = 1:NROW(positn)
for (i in 1:num.seq) {
strt <- i+(i-1)
ends <- i+((i+1)-1)
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}

}

}

seq.sub <- substring(fasta[[i]][1], positn[strt, j], positn[ends, j])
seq.ID[i] <- attr(fasta[[i]], "name")
seq.list <- list(seq = seq.sub)
seq.fasta <- rbind(seq.fasta, seq.list)

# write fasta file
file.out <- paste(ligID[k], names(positn)[j], sep = "_")
file.out <- paste(file.out, "txt", sep = ".")
write.fasta(sequences = seq.fasta, names = seq.ID, file.out = file.out, open = "w",
nbchar = 60, as.string = T)

Appendix N: Cut sequences by adding 5 amino acid at end of the 1st extracellular loop and
adds 5 amino acid at beginning and the end of the remaining extracellular loops
library(seqinr)
ligID <- c("FQUAFMNPXPXOJE-UHFFFAOYSA-N","MLQFOEOUNIRULR-UHFFFAOYSAN","YKMSTUDOGGAEJH-UHFFFAOYSA-N",
"USZPQRMQYJIDII-UHFFFAOYSA-N","BYBLEWFAAKGYCD-UHFFFAOYSAN","NKOPNLUYOHOGFZ-UHFFFAOYSA-N",
"AJLFQFYMLRXVHV-UHFFFAOYSA-N","CLQVVBPDAXJGBV-UHFFFAOYSAN","DTZDSNQYNPNCPK-UHFFFAOYSA-N",
"IKSHHOBCJKJKOG-UHFFFAOYSA-N","XLWJPQQFJNGUPA-UHFFFAOYSA-N")
num.ligID <- length(ligID)
for (k in 1:num.ligID) {
# read the positions of the extracellular loops, helices, etc
filName <- paste(ligID[k],"txt", sep = ".")
positn <- read.table(file = filName, header = T, sep = "", stringsAsFactors = F)
# read the fasta file of the gpcrs
fastaName <- paste(ligID[k], "fasta", sep = ".")
fasta <- read.fasta(file = fastaName, seqtype = "AA", as.string = T, whole.header = F,
strip.desc = F)
# get the number of gpcr in fasta file
num.seq <- (NROW(positn))/2
Eis <- c(3, 7, 11, 15)
for (j in Eis) {
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seq.fasta <- NULL
seq.ID <- c()
# row begin = i+(i-1), row end = i+((i+1)-1), i = 1:num.seq, rows = 1:NROW(positn)
for (i in 1:num.seq) {
beg <- i+(i-1)
end <- i+((i+1)-1)
strt <- positn[beg, j]
ends <- positn[end, j]

}

}

}

if (j == 3){
Positn_strt <- strt
} else {
Positn_strt <- strt - 5
}
Positn_ends <- ends + 5
seq.sub <- substring(fasta[[i]][1], Positn_strt, Positn_ends)
seq.ID[i] <- attr(fasta[[i]], "name")
seq.list <- list(seq = seq.sub)
seq.fasta <- rbind(seq.fasta, seq.list)

# write fasta file
file.out <- paste(ligID[k], names(positn)[j], sep = "_")
file.out <- paste(file.out, "txt", sep = ".")
write.fasta(sequences = seq.fasta, names = seq.ID, file.out = file.out, open = "w",
nbchar = 60, as.string = T)

Appendix O: Shell script for changing file extensions
#!/bin/bash
for dir in ./fasta_MEME/*/
do
for file in $dir*.$1
do
mv "$file" "${file%.*}.txt"
done
done
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Appendix P: Shell script for running MEME on sequences
#!/bin/bash
for dir in ./fasta_MEME_add_5/*/
do
for file in $dir*.txt
do
meme $file -protein -oc ${file%.*} -nostatus -time 18000 -mod zoops -nmotifs 100
-minw 3 -maxw 20
done
done
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